Antibodies that bind to CD3

By optimizing the variable region amino acid sequence and Fc domain of the CD3 antibody, a multispecific antibody was developed, which solved the problem of insufficient stability of CD3 antibodies and achieved high stability and low toxicity under different conditions, making it suitable for treating diseases such as cancer.

CN115698084BActive Publication Date: 2026-11-17F HOFFMANN LA ROCHE & CO AG
View PDF 90 Cites 0 Cited by

Patent Information

Application Number
CN202180043363.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-06-19
Filing Date
2021-06-17
Publication Date
2026-11-17
Estimated Expiration
2041-06-17

AI Technical Summary

Technical Problem

Existing CD3 antibodies are not stable enough in vitro and in vivo, and are easily affected by modifications such as asparagine deamidation, which affects their therapeutic efficacy and safety.

Method used

A multispecific antibody was developed that binds to CD3 and exhibits high stability. By optimizing the amino acid sequence of the variable region and the Fc domain, the antibody's resistance to degradation was enhanced, maintaining its binding activity under different conditions.

Benefits of technology

The antibody showed over 95% binding activity to CD3 after being kept at pH 6 and -80℃ for 2 weeks, and still maintained over 95% activity after being kept at pH 7.4 and 37℃ for 2 weeks. It also exhibited low toxicity and good pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004003167760001311
    Figure BDA0004003167760001311
  • Figure BDA0004003167760001321
    Figure BDA0004003167760001321
  • Figure BDA0004003167760001331
    Figure BDA0004003167760001331
Patent Text Reader

Abstract

This invention generally relates to antibodies that bind to CD3, including, for example, multispecific antibodies for activating T cells. Furthermore, this invention relates to polynucleotides encoding such antibodies, as well as vectors and host cells containing such polynucleotides. The invention further relates to methods for producing said antibodies, and to methods for using said antibodies in the treatment of diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention generally relates to antibodies that bind to CD3, including, for example, multispecific antibodies for activating T cells. Furthermore, this invention relates to polynucleotides encoding such antibodies, as well as vectors and host cells containing such polynucleotides. The invention further relates to methods for producing said antibodies, and to methods for using these antibodies in the treatment of diseases. Background Technology

[0002] CD3 (differentiation cluster 3) is a protein complex composed of four subunits (CD3γ chain, CD3δ chain, and two CD3ε chains). CD3 associates with T cell receptors and the ζ chain to generate activation signals in T lymphocytes.

[0003] CD3 has been extensively explored as a drug target. Monoclonal antibodies targeting CD3 have been used as immunosuppressive therapy for autoimmune diseases such as type 1 diabetes, or in the treatment of transplant rejection. In 1985, the CD3 antibody moromumab-CD3 (OKT3) was the first monoclonal antibody approved for clinical use in humans.

[0004] The most recent application of CD3 antibodies is in the form of bispecific antibodies, which bind to CD3 on one hand and tumor cell antigens on the other. The simultaneous binding of such antibodies to both of their targets forces a temporary interaction between the target cell and T cells, thereby activating any cytotoxic T cells and subsequently lysing the target cell.

[0005] For therapeutic purposes, an important requirement that antibodies must meet is sufficient stability both in vitro (for drug storage) and in vivo (after administration to patients).

[0006] Modifications such as asparagine deamidation are typical degradations of recombinant antibodies and can affect both in vitro stability and in vivo biological function.

[0007] Given the enormous therapeutic potential of antibodies, especially bispecific antibodies for activating T cells, there is a need for CD3 antibodies with optimized properties. Summary of the Invention

[0008] This invention provides antibodies, including multispecific (e.g., bispecific) antibodies, which bind to CD3 with good affinity and resist degradation caused by, for example, asparagine deamidation, and are therefore particularly stable (as required for therapeutic purposes). The provided (multispecific) antibodies combine good efficacy (e.g., killing of target cells) with manufacturability and low toxicity (e.g., not activating T cells in the absence of target cells) and favorable pharmacokinetic properties.

[0009] As shown herein, the CD3-binding antibodies (including multispecific antibodies) provided by the present invention retain more than about 95% of their binding activity after 2 weeks at pH 7.4 and 37°C, relative to their binding activity after 2 weeks at pH 6 and -80°C, as determined by surface plasmon resonance (SPR).

[0010] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody includes a first antigen-binding domain, the first antigen-binding domain comprising...

[0011] (i) Heavy chain variable region (VH), which is selected from the group consisting of the following:

[0012] (a) VH, which includes the heavy chain complementarity determination region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4 and HCDR 3 of SEQ ID NO:10;

[0013] (b) VH, which includes HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4 and HCDR 3 of SEQ ID NO:12;

[0014] (c)VH, which includes HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5 and HCDR 3 of SEQ ID NO:9;

[0015] (d) VH, which includes HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11; or

[0016] (e)VH, which includes HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7 and HCDR 3 of SEQ ID NO:13;

[0017] as well as

[0018] (ii) Light chain variable region (VL) containing the light chain complementarity determination region (LCDR) of SEQ ID NO:20.

[0019] 1. LCDR 2 of SEQ ID NO:21 and LCDR 3 of SEQ ID NO:22.

[0020] In one aspect, the VH contains at least about 95%, 96%, 97%, 98%, 99%, or 100% of the same amino acid sequence as the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19; and / or the VL contains at least about 95%, 96%, 97%, 98%, 99%, or 100% of the same amino acid sequence as the amino acid sequence of SEQ ID NO:23.

[0021] In another aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising a VH sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19 and a VL sequence of SEQ ID NO:23.

[0022] In one respect, the first antigen-binding domain is the Fab molecule.

[0023] In one respect, the antibody contains an Fc domain consisting of a first subunit and a second subunit.

[0024] In one respect, the antibody includes a second antigen-binding domain that binds to a second antigen and, optionally, a third antigen-binding domain.

[0025] In one respect, the second antigen-binding domain and / or, in the presence of the third antigen-binding domain, are Fab molecules.

[0026] In one aspect, the first antigen-binding domain is a Fab molecule in which the variable domains VL and VH of the Fab light chain and the Fab heavy chain are interchanged with each other or the constant domains CL and CH1 are interchanged with each other, especially the variable domains VL and VH are interchanged with each other.

[0027] In one respect, the second antigen-binding domain and, in their presence, the third antigen-binding domain are typical of Fab molecules.

[0028] In one aspect, the second antigen-binding domain and, in its presence, the third antigen-binding domain are Fab molecules, wherein in the constant domain CL, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering); while in the constant domain CH1, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing).

[0029] In one aspect, the first antigen-binding domain and the second antigen-binding domain are fused together, optionally via a peptide linker.

[0030] In one aspect, the first antigen-binding domain and the second antigen-binding domain are each Fab molecules, and (i) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, or (ii) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain.

[0031] In one aspect, the first antigen-binding domain, the second antigen-binding domain, and, in the presence, the third antigen-binding domain are each Fab molecules, and the antibody comprises an Fc domain consisting of a first subunit and a second subunit; wherein (i) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or (ii) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; and the third antigen-binding domain, in the presence, is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

[0032] In one aspect, the Fc domain is the IgG, particularly the IgG1 Fc domain. In another aspect, the Fc domain is the human Fc domain. In one aspect, the Fc domain contains modifications that promote the association of the first and second subunits of the Fc domain. In one aspect, the Fc domain contains one or more amino acid substitutions that reduce binding to the Fc receptor and / or effector function.

[0033] In one respect, the second antigen is a target cell antigen, particularly a tumor cell antigen.

[0034] In one aspect, the second antigen is TYRP-1. In one aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprise VH and VL, wherein the VH comprises HCDR 1 of SEQ ID NO:24, HCDR 2 of SEQ ID NO:25, and HCDR 3 of SEQ ID NO:26; and the VL comprises LCDR 1 of SEQ ID NO:28, LCDR 2 of SEQ ID NO:29, and LCDR 3 of SEQ ID NO:30. In one aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprise VH and / or VL, wherein the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:27; and the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:31.

[0035] In one respect, the second antigen is CEA. In one aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprises: (i) VH, which comprises HCDR 1 of SEQ ID NO:53, HCDR 2 of SEQ ID NO:54, and HCDR 3 of SEQ ID NO:55; and VL, which comprises LCDR 1 of SEQ ID NO:57, LCDR 2 of SEQ ID NO:58, and LCDR 3 of SEQ ID NO:59; (ii) VH, which comprises HCDR 1 of SEQ ID NO:105, HCDR 2 of SEQ ID NO:106, and HCDR 3 of SEQ ID NO:107; and VL, which comprises LCDR 1 of SEQ ID NO:109, LCDR 2 of SEQ ID NO:110, and LCDR 3 of SEQ ID NO:111; or (iii) VH, which comprises HCDR 1 of SEQ ID NO:113, HCDR 2 of SEQ ID NO:114, and HCDR 3 of SEQ ID NO:115. 3; and VL, which includes LCDR 1 of SEQ ID NO:117, LCDR 2 of SEQ ID NO:118, and LCDR 3 of SEQ ID NO:119. In one aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprises: (i) VH, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:56; and / or VL, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:60; (ii) VH, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:108; and / or VL, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:112; or (iii) VH, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:112; or (iii) VH, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:60; NO:116 has an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:120; and / or VL, which contains an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:120.

[0036] In one aspect, the second antigen is GPRC5D. In another aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprise VH and VL, wherein the VH comprises HCDR 1 of SEQ ID NO:61, HCDR 2 of SEQ ID NO:62, and HCDR 3 of SEQ ID NO:63; and the VL comprises LCDR 1 of SEQ ID NO:65, LCDR 2 of SEQ ID NO:66, and LCDR 3 of SEQ ID NO:67. In another aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprise VH and / or VL, wherein the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:64; and the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:68.

[0037] In one aspect, the second antigen is CD19. In one aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprises: (i) VH, which comprises HCDR 1 of SEQ ID NO:75, HCDR 2 of SEQ ID NO:76, and HCDR 3 of SEQ ID NO:77; and VL, which comprises LCDR 1 of SEQ ID NO:79, LCDR 2 of SEQ ID NO:80, and LCDR 3 of SEQ ID NO:81; or (ii) VH, which comprises HCDR 1 of SEQ ID NO:83, HCDR 2 of SEQ ID NO:84, and HCDR 3 of SEQ ID NO:85; and VL, which comprises LCDR 1 of SEQ ID NO:87, LCDR 2 of SEQ ID NO:88, and LCDR 3 of SEQ ID NO:89. In one aspect, the second antigen-binding domain and, in the presence, the third antigen-binding domain comprises: (i) VH, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:78; and / or VL, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:82; or (ii) VH, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:86; and / or VL, which comprises at least about 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence identical to that of SEQ ID NO:90.

[0038] According to another aspect of the invention, isolated polynucleotides encoding the antibodies of the invention and host cells containing the isolated polynucleotides of the invention are provided.

[0039] On the other hand, a method for producing CD3-binding antibodies is provided, the method comprising the steps of: (a) culturing host cells of the invention under conditions suitable for expressing the antibody, and optionally (b) recovering the antibody. The invention also covers CD3-binding antibodies produced by the method of the invention.

[0040] The present invention further provides a pharmaceutical composition comprising the antibody and pharmaceutical carrier of the present invention.

[0041] This invention also covers methods of using the antibody and pharmaceutical compositions of the invention. In one aspect, the invention provides an antibody or pharmaceutical composition according to the invention for use as a medicament. In another aspect, an antibody or pharmaceutical composition according to the invention is provided for treating a disease. In a specific aspect, the disease is cancer.

[0042] The invention also provides the use of the antibody or pharmaceutical composition according to the invention in the manufacture of a medicament, and the use of the antibody or pharmaceutical composition according to the invention in the manufacture of a medicament for treating diseases, particularly cancer. The invention further provides a method of treating a disease in an individual, comprising administering an effective amount of the antibody or pharmaceutical composition according to the invention to said individual. Attached Figure Description

[0043] Figure 1Exemplary configurations of the (multispecific) antibodies of the present invention. (A, D) Schematic diagram of a "1+1 CrossMab" molecule. (B, E) Schematic diagram of a "2+1 IgG Crossfab" molecule, wherein the order of the Crossfab and Fab components alternates ("inverted"). (C, F) Schematic diagram of a "2+1 IgG Crossfab" molecule. (G, K) Schematic diagram of a "1+1 IgG Crossfab" molecule, wherein the order of the Crossfab and Fab components alternates ("inverted"). (H, L) Schematic diagram of a "1+1 IgG Crossfab" molecule. (I, M) Schematic diagram of a "2+1 IgG Crossfab" molecule having two CrossFabs. (J, N) Schematic diagram of a "2+1 IgG Crossfab" molecule having two CrossFabs, wherein the order of the Crossfab and Fab components alternates ("inverted"). (O, S) Schematic diagram of a "Fab-Crossfab" molecule. (P, T) Schematic diagram of a "Crossfab-Fab" molecule. (Q, U) Schematic diagram of the "(Fab)2-Crossfab" molecule. (R, V) Schematic diagram of the "Crossfab-(Fab)2" molecule. (W, Y) Schematic diagram of the "Fab-(Crossfab)2" molecule. (X, Z) Schematic diagram of the "(Crossfab)2-Fab" molecule. Black dots: Optional modifications in the Fc domain that promote heterodimerization. ++, --: Optional introduction of amino acids with opposite charges in the CH1 and CL domains. Crossfab molecules are described as containing the exchange of VH and VL regions, but can alternatively include the exchange of CH1 and CL domains—in aspects where no charge modification is introduced in the CH1 and CL domains.

[0044] Figure 2 (A) Schematic diagram of the T-cell bispecific antibody (TCB) molecules used in the examples. All tested TCB antibody molecules were generated as a charge-modified “2+1 IgG CrossFab, inverted” (VH / VL exchange in the CD3 conjugate, charge modification in the target cell antigen conjugate, EE = 147E, 213E; RK = 123R, 124K). (BE) Components used to assemble TCBs: light chains of anti-TYRP1 Fab molecules with charge modifications in CH1 and CL (B); light chains of anti-CD3 crossFab molecules (C); heavy chains with gluten and PG LALA mutations in the Fc region (D); heavy chains with gluten and PG LALA mutations in the Fc region (E).

[0045] Figure 3Schematic diagram of the surface plasmon resonance (SPR) device used in Example 3. Anti-PG antibody coupled to the C1 sensor chip. Human CD3 and cynomolgus monkey CD3 (fused to the Fc region) were passed through its surface to analyze the interaction between the anti-CD3 antibody and CD3 in the TCB.

[0046] Figure 4 TCBs containing optimized anti-CD3 antibodies were tested in Jurkat NFAT reporter gene analysis using CHO-K1 TYRP1 clone 76 as target cells. (Compared to TCBs containing CD3...) orig The TCB was compared. Activation of Jurkat NFAT reporter cells was determined by measuring luminescence after 4 hours (A) and 24 hours of treatment.

[0047] Figure 5 When using an optimized anti-CD3 antibody or parental conjugate CD3... orig The tumor-killing effect of PBMCs from healthy donors on the melanoma cell line M150543 was evaluated during TCB treatment. The tumor-killing effect was measured by quantifying LDH release after 24 hours (A) and 48 hours (B).

[0048] Figure 6 In the presence of the M150543 melanoma cell line as target cells, analysis was performed on the upregulation of CD25 and CD69 in CD8 T cells (A, B) and CD4 T cells (C, D) from healthy donor PBMCs treated with optimized anti-CD3 antibodies or parental conjugates. orig The cells were treated with TCB. Analysis was performed by flow cytometry 48 hours later.

[0049] Figure 7 In the absence of tumor target cells, CD25 expression on CD8 (A) and CD4 T cells (B) of PBMCs from healthy donors was analyzed. These donors were treated with optimized anti-CD3 antibodies or parental conjugates containing CD3. orig The cells were treated with TCB. Analysis was performed by flow cytometry 48 hours later.

[0050] Figure 8 CEACAM5-TCB molecules (containing optimized anti-CD3 antibodies or parental conjugates CD3) orig The binding of CD3-expressing T cells (A) and CEA-positive tumor cells (B), as measured by flow cytometry.

[0051] Figure 9 The CEACAM5-TCB molecule (containing an optimized anti-CD3 antibody or parental conjugate CD3) origTumor cell lysis of CEA-positive tumor cells mediated by PBMCs from healthy donors was observed. Tumor cell killing was measured by quantifying LDH release after 24 hours (A) and 48 hours (B).

[0052] Figure 10 The binding of GPRC5D-TCB molecules (containing an optimized anti-CD3 antibody) to CD3-expressing T cells (A) and GPRC5D-positive cells (B), as measured by flow cytometry.

[0053] Figure 11 Tumor cell lysis of GPRC5D-positive cells mediated by GPRC5D-TCB molecules (containing an optimized anti-CD3 antibody) was performed using PBMCs from healthy donors. Tumor cell killing activity was measured by quantifying LDH release after 20 hours.

[0054] Figure 12 The binding of the CD19-TCB antibody to CD3-expressing Jurkat cells (A) and CD19-expressing Z-138 (B) and Nalm-6 (C) cells, as measured by flow cytometry.

[0055] Figure 13 Target-specific killing of CD19+ target cells induced by CD19-TCB antibody. (A) Z-138 target cells, (B) Nalm-6 target cells.

[0056] Figure 14 T cell activation induced by CD19-TCB antibody after killing Z-138 target cells. (A) CD25 expression on CD4 T cells, (B) CD69 expression on CD4 T cells, (C) CD107 expression on CD4 T cells, (D) CD25 expression on CD8 T cells, (E) CD69 expression on CD8 T cells, (F) CD107 expression on CD8 T cells.

[0057] Figure 15 T cell activation induced by CD19-TCB antibody after killing Nalm-6 target cells. (A) CD25 expression on CD4 T cells, (B) CD69 expression on CD4 T cells, (C) CD107 expression on CD4 T cells, (D) CD25 expression on CD8 T cells, (E) CD69 expression on CD8 T cells, (F) CD107 expression on CD8 T cells.

[0058] Figure 16(A) Schematic diagram of the monovalent IgG molecule generated in Example 19. The monovalent IgG molecule is generated as human IgG1 and has VH / VL exchange in the CD3 conjugate. (BE) Components used to assemble monovalent IgG: light chain with anti-CD3 cross-Fab molecule (B), heavy chain with gluten and PG LALA mutations in the Fc region (C), and heavy chain with gluten and PG LALA mutations in the Fc region (D).

[0059] Figure 17 Design of the in vivo study in Example 26.

[0060] Figure 18 In Example 26, body weight changes were observed after treatment with different doses of CD19-TCB or CD20-TCB. Each group had n = 3 mice. Mean ± SEM values ​​were used.

[0061] Figure 19 In the study of Example 26, with or without oxotuzumab ( Under pretreatment (GPT), cytokine release in serum 4 hours after treatment with CD19-TCB or CD20-TCB. (A) MIP-1β, (B) IL-6, (C) IFN-γ, (D) IL-5, (E) GM-CSF, (F) TNF-α, (G) IL-2, (H) IL-1β, (I) IL-13, (J) MCP1, (K) IL-8, (L) IL-10, (M) G-CSF, (N) IL-12p70, (O) IL-17. The bars in each image, from left to right: CD19-TCB 0.5 mg / kg, CD19-TCB 0.15 mg / kg, CD19-TCB 0.05 mg / kg, GPT+CD19-TCB 0.5 mg / kg, CD20-TCB 0.15 mg / kg, GPT+CD20-TCB 0.15 mg / kg. Mean + SEM.

[0062] Figure 20 In the study of Example 26, with or without oxotuzumab ( B cell counts in the blood at 4, 24, and 72 hours after treatment with CD19-TCB or CD20-TCB in the case of pretreatment (GPT). Mean + SEM.

[0063] Figure 21 Treatment plan and experimental setup. Subcutaneous transplantation of patient-derived xenografts (PDX) (5 million cells) into humanized NSG mice. Tumor volume was calculated using caliper measurements. When they reached 200 mm... 3Mice were randomly divided into 8 groups based on tumor size. They were then injected weekly with either the mediator or 0.5 mg / kg CD19-TCB.

[0064] Figure 22 The effect of CD19-TCB treatment on tumor growth. For n=7 mice in group B and n=8 mice in group A, treatment was administered twice weekly (volume <1000mm²). 3 ) or three times (volume ≥ 1000 mm) 3 The tumor volume is calculated using caliper measurements, such as... Figure 21 As described above. The mean + SD of *p≤0.05, **p≤0.01, and ***p≤0.001 were determined by the Mann-Whitney test. Arrows indicate each of the four treatments administered with CD19-TCB or a mediator. Detailed Implementation

[0065] I. Definition

[0066] Unless otherwise defined below, the terminology used herein is generally as it is used in the art.

[0067] As used herein, the terms “first,” “second,” or “third” relating to antigen-binding domains, etc., are used for ease of distinction when there are more than one of each type of part. Unless explicitly stated otherwise, the use of these terms is not intended to assign a particular order or orientation to the parts.

[0068] The terms "anti-CD3 antibody" and "CD3-binding antibody" refer to antibodies that bind to CD3 with sufficient affinity, making them suitable for use as diagnostic and / or therapeutic agents targeting CD3. In one aspect, for example, as measured by surface plasmon resonance (SPR), anti-CD3 antibodies bind to less than about 10% of unrelated, non-CD3 proteins. In other aspects, CD3-binding antibodies have dissociation constants (Ki) ≤1 μM, ≤500 nM, ≤200 nM, or ≤100 nM. D For example, by measuring SPR, when the antibody's K... D When the concentration is 1 μM or less, the antibody is said to "specifically bind" to CD3. In some respects, anti-CD3 antibodies bind to epitopes of CD3 that are conserved in CD3 from different species.

[0069] The term “antibody” is used in the broadest sense and encompasses a wide variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, as long as they exhibit the desired antigen-binding activity.

[0070] An "antibody fragment" is a molecule other than a complete antibody that contains a portion of the complete antibody that binds to the antigen bound by the complete antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; bisomatic antibodies; linear antibodies; single-chain antibody molecules (e.g., scFv and scFab); single-domain antibodies; and multispecific antibodies formed from antibody fragments. For a review of some antibody fragments, see Hollinger and Hudson, Nature Biotechnology 23:1126-1136 (2005).

[0071] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used interchangeably in this document to refer to antibodies that have a structure substantially similar to that of natural antibodies.

[0072] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies, meaning that, apart from possible variant antibodies, the individual antibodies in this population are identical and / or bind to the same epitopes, such as those containing naturally occurring mutations or generated during the production of the monoclonal antibody preparation. These variants are typically present in trace amounts. In contrast to polyclonal antibody preparations, which typically comprise different antibodies targeting different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation targets a single determinant on the antigen. Therefore, the modifier "monoclonal" indicates that the antibody is characterized by being obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring the antibody to be produced by any particular method. For example, monoclonal antibodies can be prepared using a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci. Such methods and other exemplary methods for preparing monoclonal antibodies are described herein.

[0073] "Isolated" antibodies are antibodies that have been separated from components in their natural environment. In some aspects, antibodies are purified to a purity greater than 95% or 99%, determined by methods such as electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC, affinity chromatography, size exclusion chromatography). For a review of methods for assessing antibody purity, see, for example, Flatman et al., J. Chromatogr. B 848:79-87 (2007). In some aspects, the antibodies provided by this invention are isolated antibodies.

[0074] The term "chimeric" antibody refers to an antibody in which a portion of the heavy chain and / or light chain originates from a specific source or species, while the remainder of the heavy chain and / or light chain originates from a different source or species.

[0075] "Humanized" antibodies refer to chimeric antibodies that contain amino acid residues from non-human CDRs and amino acid residues from human FRs. In some aspects, humanized antibodies will substantially contain all at least one, typically both, variable domains, wherein all or substantially all CDRs correspond to the CDRs of the non-human antibody, and all or substantially all FRs correspond to the FRs of the human antibody. Such variable domains are referred to herein as "humanized variable regions." Humanized antibodies may optionally contain at least a portion of the antibody constant region derived from a human antibody. In some aspects, some FR residues in a humanized antibody are replaced by corresponding residues from a non-human antibody (e.g., an antibody from which the CDR residues are derived), for example, to restore or improve antibody specificity or affinity. The "humanized form" of an antibody (e.g., a non-human antibody) refers to an antibody that has undergone humanization.

[0076] A "human antibody" is an antibody whose amino acid sequence corresponds to that of antibodies produced by humans or human cells, or to a non-human antibody derived from a complete human antibody library or other human antibody-coding sequences. This definition of a human antibody specifically excludes humanized antibodies containing non-human antigen-binding residues. In some respects, human antibodies are derived from non-human transgenic mammals, such as mice, rats, or rabbits. In some respects, human antibodies are derived from hybridoma cell lines. Antibodies or antibody fragments isolated from human antibody libraries in this paper are also considered human antibodies or human antibody fragments.

[0077] The term "antigen-binding domain" refers to a portion of an antibody that contains a region that binds partially or entirely to and is complementary to an antigen. Antigen-binding domains can be provided, for example, by one or more antibody variable domains (also called antibody variable regions). In a preferred aspect, the antigen-binding domain comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).

[0078] The term "variable region" or "variable domain" refers to a domain of the antibody heavy or light chain involved in antibody-antigen binding. The variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies typically have similar structures, with each domain containing four conserved frame regions (FRs) and complementarity-determining regions (CDRs). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman & Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies binding to a specific antigen can be isolated using either the VH or VL domain from the antibody binding to that antigen to screen libraries for complementary VL or VH domains. See, for example, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991). As used in this paper, the “Kabat numbering” associated with variable region sequences refers to the numbering system proposed by Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991).

[0079] As used herein, the amino acid positions of all constant regions and constant domains of the heavy and light chains are numbered according to the Kabat numbering system described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), and are referred to herein as “according to Kabat numbering” or “Kabat numbering”. Specifically, the Kabat numbering system (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), pp. 647–660) is used for the κ and λ isoform light chain constant domain CL, and the Kabat EU index numbering system (see pp. 661–723) is used for the heavy chain constant domains (CH1, hinge, CH2, and CH3), which is further clarified herein by referring to this case as “according to Kabat EU indexing” or “Kabat EU indexing”.

[0080] As used herein, the term "hypervariant region" or "HVR" refers to the regions within the variable domains of an antibody that are sequence-highly variable and determine antigen-binding specificity, such as "complementarity-determining regions" ("CDRs"). Generally, an antibody contains six CDRs: three in the VH (HCDR1, HCDR2, HCDR3) and three in the VL (LCDR1, LCDR2, LCDR3). Exemplary CDRs in this document include:

[0081] (a) Highly variable rings appearing at the following amino acid residues: 26 to 32 (L1), 50 to 52 (L2), 91 to 96 (L3), 26 to 32 (H1), 53 to 55 (H2) and 96 to 101 (H3) (Chothia and Lesk, J.Mol.Biol.196:901-917(1987));

[0082] (b) CDRs appearing at the following amino acid residues: 24–34 (L1), 50–56 (L2), 89–97 (L3), 31–35b (H1), 50–65 (H2), and 95–102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and

[0083] (c) Antigen contact sites appearing at the following amino acid residues: 27c to 36 (L1), 46 to 55 (L2), 89 to 96 (L3), 30 to 35b (H1), 47 to 58 (H2), and 93 to 101 (H3) (MacCallum et al., J.Mol.Biol.262:732-745 (1996)).

[0084] Unless otherwise specified, the CDR is determined according to the method described by Kabat et al., citing above. Those skilled in the art will understand that the CDR name may also be determined according to the method described by Chothia, citing above, the method described by McCallum, citing above, or any other scientifically accepted naming system.

[0085] "Frame" or "FR" refers to the variable domain residues other than the complementarity-determining region (CDR). A variable domain FR typically consists of four FR domains: FR1, FR2, FR3, and FR4. Therefore, HVR sequences and FR sequences usually appear in VH (or VL) in the following order: FR1-HCDR1(LCDR1)-FR2-HCDR2(LCDR2)-FR3-HCDR3(LCDR3)-FR4.

[0086] Unless otherwise specified, CDR residues and other residues (e.g., FR residues) in the variable domain are referenced herein by Kabat et al., ibid.

[0087] For the purposes of this document, a “recipient human frame” is a frame that comprises an amino acid sequence of a light chain variable domain (VL) frame or a heavy chain variable domain (VH) frame derived from the human immunoglobulin frame or the human common frame as defined below. A recipient human frame “derived from” the human immunoglobulin frame or the human common frame may contain the same amino acid sequence as said human immunoglobulin frame or human common frame, or it may contain amino acid sequence variations. In some aspects, the number of amino acid variations is 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer. In some aspects, the VL recipient human frame is sequenceally identical to the VL human immunoglobulin frame sequence or the human common frame sequence.

[0088] The “human common framework” is a framework that represents the most frequently occurring amino acid residues in the selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences comes from a subgroup of variable domain sequences. Typically, these subgroups are those described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1-3.

[0089] The term "immunoglobulin molecule" in this article refers to a protein with the structure of naturally occurring antibodies. For example, IgG immunoglobulins are heterotetrameric glycoproteins of approximately 150,000 Daltons, composed of two light chains and two heavy chains linked by disulfide bonds. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH) (also called a variable heavy chain domain or heavy chain variable region), followed by three constant domains (CH1, CH2, and CH3) (also called heavy chain constant regions). Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL) (also called a light chain variable domain or light chain variable region), followed by a constant light chain (CL) domain (also called a light chain constant region). The heavy chains of immunoglobulins can be classified into one of five types: α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM). Some of these can be further subdivided into multiple subtypes, such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1), and α2 (IgA2). The light chains of immunoglobulins can be classified into one of two types based on the amino acid sequence of their constant domains: κ and λ. Immunoglobulins are essentially composed of two Fab molecules linked by an immunoglobulin hinge region and an Fc domain.

[0090] The "class" of an antibody or immunoglobulin refers to the type of constant domain or region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of these antibodies can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The constant domains of the heavy chain corresponding to different classes of immunoglobulins are respectively called α, δ, ε, γ, and μ.

[0091] "Fab molecule" refers to a protein composed of the VH and CH1 domains of the heavy chain ("Fab heavy chain") of an immunoglobulin and the VL and CL domains of the light chain ("Fab light chain").

[0092] The term "crossfab" refers to a Fab molecule in which the variable or constant domains of the Fab heavy and light chains are exchanged (i.e., replaced). Specifically, a crossfab molecule comprises a peptide chain consisting of a light chain variable domain VL and a heavy chain constant domain 1CH1 (VL-CH1, N-terminal to C-terminal direction), and a peptide chain consisting of a heavy chain variable domain VH and a light chain constant domain CL (VH-CL, N-terminal to C-terminal direction). For clarity, in crossfab molecules where the variable domains of the Fab light and heavy chains are exchanged, the peptide chain containing the heavy chain constant domain 1CH1 is referred to herein as the "heavy chain" of the (cross)fab molecule. Conversely, in crossfab molecules where the constant domains of the Fab light and heavy chains are exchanged, the peptide chain containing the heavy chain variable domain VH is referred to herein as the "heavy chain" of the (cross)fab molecule.

[0093] In contrast, the so-called "conventional" Fab molecule refers to the Fab molecule in its natural form, that is, the heavy chain (VH-CH1, in the direction from the N end to the C end) consisting of a heavy chain with variable and constant structural domains, and the light chain (VL-CL, in the direction from the N end to the C end) consisting of a light chain with variable and constant structural domains.

[0094] The term "Fc domain" or "Fc region" used herein is used to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of a constant region. This term includes both native sequence Fc regions and variant Fc regions. In one aspect, the human IgG heavy chain Fc region extends from Cys226 or Pro230 to the C-terminus of the heavy chain. However, antibodies produced by host cells can undergo post-translational cleavage of one or more (particularly one or two) amino acids from the C-terminus of the heavy chain. Therefore, antibodies produced by host cells by expressing a specific nucleic acid molecule encoding the full-length heavy chain can comprise the full-length heavy chain, or the antibody can comprise a cleaved variant of the full-length heavy chain. This may be the case when the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, according to the Kabat EU index number). Therefore, the C-terminal lysine (Lys447) or the C-terminal glycine (Gly446) and lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified, the amino acid sequence of a heavy chain containing an Fc region (or a subunit of an Fc domain as defined herein) is represented herein as without a C-terminal glycine-lysine dipeptide. In one aspect, a heavy chain containing an Fc region (subunit) as specified herein is included in an antibody according to the invention, the heavy chain containing an additional C-terminal glycine-lysine dipeptide (G446 and K447, according to Kabat EU index numbers). In another aspect, a heavy chain containing an Fc region (subunit) as specified herein is included in an antibody according to the invention, the heavy chain containing an additional C-terminal glycine residue (G446, according to Kabat EU index number). Unless otherwise specified herein, the amino acid residues in the Fc region or constant region are numbered according to the EU numbering system (also known as the EU index), as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also above). As used herein, a “subunit” of the Fc domain refers to one of the two polypeptides that form the dimer Fc domain, namely a polypeptide containing the C-terminal constant region of the immunoglobulin heavy chain, which is capable of stable self-association. For example, the subunit of the IgG Fc domain contains the IgG CH2 constant domain and the IgG CH3 constant domain.

[0095] The term "fusion" refers to the linking of components (such as Fab molecules and Fc domain subunits) directly or via one or more peptide linkers through peptide bonds.

[0096] The term "multispecific" means that the antibody can specifically bind to at least two different antigenic determinants. A multispecific antibody can be, for example, a bispecific antibody. Typically, a bispecific antibody contains two antigen-binding sites, each of which is specific to a different antigenic determinant. In some respects, the multispecific (e.g., bispecific) antibody can bind to two antigenic determinants simultaneously, particularly two antigenic determinants expressed on two different cells.

[0097] As used herein, the term "valence" indicates the presence of a specified number of antigen-binding sites in an antigen-binding molecule. Therefore, the term "monovalently bound to antigen" indicates the presence of one (and no more than one) antigen-binding site in an antigen-binding molecule that is specific to the antigen.

[0098] An "antigen binding site" is a site on an antigen-binding molecule that provides an interaction with an antigen; it is typically one or more amino acid residues. For example, the antigen binding site of an antibody contains amino acid residues from its complementarity-determining region (CDR). Natural immunoglobulin molecules usually have two antigen binding sites, while Fab molecules usually have a single antigen binding site.

[0099] As used herein, the term "antigenic determinant" or "antigen" refers to a site on a polypeptide macromolecule (e.g., a continuous amino acid sequence or a conformation composed of different regions of non-continuous amino acids) to which an antigen-binding domain binds, thereby forming an antigen-binding domain-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, in serum, and / or in the extracellular matrix (ECM). In a preferred aspect, the antigen is a human protein.

[0100] Unless otherwise specified, “CD3” means any naturally occurring CD3 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term covers “full-length” unprocessed CD3, as well as any form of CD3 produced by cellular processing. The term also covers naturally occurring variants of CD3, such as splice variants or allelic variants. In one respect, CD3 is human CD3, particularly the ε subunit of human CD3 (CD3ε). The amino acid sequence of human CD3ε is shown in SEQ ID NO:45 (no signal peptide). See also UniProt (www.uniprot.org) accession number P07766 (version 189), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_000724.1. In another respect, CD3 is cynomolgus monkey (Macacafascicularis) CD3, particularly cynomolgus monkey CD3ε. The amino acid sequence of cynomolgus CD3ε is shown in SEQ ID NO:46 (no signal peptide). See also NCBI GenBank no. BAB71849.1. In some aspects, the antibodies of the present invention bind to epitopes of CD3 (particularly human and cynomolgus CD3) conserved in CD3 antigens from different species. In a preferred aspect, the antibodies bind to human CD3.

[0101] As used herein, "target cell antigen" refers to an antigenic determinant present on the surface of a target cell, such as a cell in a tumor (e.g., a cancer cell or a cell in the tumor stroma) (in this case, "tumor cell antigen"). Preferably, the target cell antigen is not CD3, and / or is expressed on cells different from CD3. In one aspect, the target cell antigen is TYRP-1, particularly human TYRP-1. In another aspect, the target cell antigen is CEA, particularly human CEA. In yet another aspect, the target cell antigen is GPRC5D, particularly human GPRC5D. In yet another aspect, the target cell antigen is CD19, particularly human CD19.

[0102] “TYRP1” or “TYRP-1” stands for Tyrosinase-associated protein 1 (also known as 5,6-dihydroxyindole-2-carboxylic acid oxidase) and refers to any naturally occurring TYRP-1 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. The term covers “full-length” unprocessed TYRP1, as well as any form of TYRP-1 produced by cellular processing. The term also covers naturally occurring variants of TYRP-1, such as splice variants or allelic variants. In one respect, TYRP-1 is human TYRP-1. For human proteins, see UniProt (www.uniprot.org) accession number P17643 (version 195), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_000541.1. In some respects, the antibodies of the present invention bind to epitopes of TYRP-1 (particularly human and cynomolgus monkey TYRP-1) that are conserved in TYRP-1 antigens from different species. In a preferred respect, the antibodies bind to human TYRP-1.

[0103] “CEA” stands for carcinoembryonic antigen (also known as carcinoembryonic antigen-associated cell adhesion molecule 5 (CEACAM5)) and refers to any naturally occurring CEA from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. The term covers “full-length” unprocessed CEA, as well as any form of CEA produced by cellular processing. The term also covers naturally occurring variants of CEA, such as splice variants or allelic variants. In one aspect, the CEA is human CEA. For human proteins, see UniProt (www.uniprot.org) accession number P06731 (version 195), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_004354.2. In some aspects, the antibodies of the present invention bind to epitopes of CEA (particularly human and cynomolgus monkey CEA) that are conserved in CEA antigens from different species. In a preferred aspect, the antibodies bind to human CEA.

[0104] “GPRC5D” stands for Group 5 member D of the G protein-coupled receptor family C and refers to any naturally occurring GPRC5D from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise stated. The term covers “full-length” unprocessed GPRC5D, as well as any form of GPRC5D produced by cellular processing. The term also covers naturally occurring variants of GPRC5D, such as splice variants or allelic variants. In one aspect, GPRC5D is human GPRC5D. For the human protein, see UniProt (www.uniprot.org) accession number Q9NZD1 (version 131), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_061124.1. In some aspects, the antibodies of the present invention bind to epitopes of GPRC5D conserved in GPRC5D antigens from different species (particularly human and cynomolgus monkey GPRC5D). In a preferred embodiment, the antibody binds to human GPRC5D.

[0105] "CD19" stands for cluster 19 of differentiation (also known as B lymphocyte antigen CD19 or B lymphocyte surface antigen B4) and refers to any naturally occurring CD19 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. The term covers "full-length" unprocessed CD19, as well as any form of CD19 produced by cellular processing. The term also covers naturally occurring variants of CD19, such as splice variants or allelic variants. In one respect, CD19 is human CD19. For the human protein, see UniProt (www.uniprot.org) accession number P15391 (version 211), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_001761.3. In some respects, the antibodies of the present invention bind to epitopes of CD19 (particularly human and cynomolgus monkey CD19) that are conserved in CD19 antigens from different species. In a preferred aspect, the antibodies bind to human CD19.

[0106] “Affinity” refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise stated, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its partner Y can generally be determined by the dissociation constant (K). DAffinity can be measured by well-established methods known in the art, including those described herein. A preferred method for measuring affinity is surface plasmon resonance (SPR).

[0107] "Affinity-mature" antibodies are those that have one or more alterations in one or more complementarity-determining regions (CDRs) that result in improved affinity of the antibody for the antigen compared to parental antibodies without such alterations.

[0108] "Reduced binding" (e.g., reduced binding to the Fc receptor) refers to a decrease in affinity for the corresponding interaction, as measured, for example, by SPR. For clarity, the term also includes reducing the affinity to zero (or below the detection limit of the analytical method), i.e., completely eliminating the interaction. Conversely, "increased binding" refers to an increase in binding affinity for the corresponding interaction.

[0109] As used herein, “T cell activation” refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from: proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. Appropriate assays for measuring T cell activation are known in the art and are described herein.

[0110] "Modification that promotes association between the first and second subunits of the Fc domain" refers to manipulation of the peptide backbone or post-translational modification of the Fc domain subunits that reduces or prevents the association of a polypeptide containing an Fc domain subunit with the same polypeptide to form a homodimer. As used herein, "association-promoting modification" preferably includes individual modification of each of the two Fc domain subunits (i.e., the first and second subunits of the Fc domain) to which association is desired, wherein the modifications are complementary to each other to promote the association of the two Fc domain subunits. For example, association-promoting modification may alter the structure or charge of one or both of the Fc domain subunits to make their association sterically or electrostatically favorable, respectively. Thus, (hetero)dimerization occurs between a polypeptide containing a first Fc domain subunit and a polypeptide containing a second Fc domain subunit, which may differ with respect to additional components (e.g., antigen-binding domains) fused to each subunit. In some aspects, modifications that promote association between the first and second subunits of the Fc domain include amino acid mutations, specifically amino acid substitutions, in the Fc domain. In a preferred aspect, the modifications that promote association between the first and second subunits of the Fc domain include individual amino acid mutations, particularly amino acid substitutions, in each of the two subunits of the Fc domain.

[0111] The term "effective function" refers to those biological activities attributable to the Fc region of an antibody that vary with antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), cytokine secretion, antigen uptake by immune complex-mediated antigen-presenting cells, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

[0112] "Activated Fc receptors" are Fc receptors that, upon binding to the Fc domain of an antibody, trigger signal transduction events that stimulate effector functions in cells carrying the receptor. Human activated Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).

[0113] Antibody-dependent cell-mediated cytotoxicity (ADCC) is an immune mechanism that causes immune effector cells to lyse antibody-coated target cells. Target cells are cells that specifically bind to an antibody or a derivative thereof containing an Fc region, typically via the N-terminal protein portion of the Fc region. As used herein, the term “reduced ADCC” is defined as a reduction in the number of target cells lysed within a given time period at a given antibody concentration in the culture medium surrounding the target cells via the ADCC mechanism defined above, and / or an increase in the antibody concentration necessary to achieve lysis of a given number of target cells within a given time period via the ADCC mechanism in the culture medium surrounding the target cells. Reduced ADCC is ADCC mediated by the same antibody produced from the same type of host cells but not engineered, using the same standard methods of production, purification, formulation, and storage (such methods are known to those skilled in the art). For example, reduced ADCC mediated by an antibody containing an amino acid substitution in the Fc domain that reduces ADCC is relative to ADCC mediated by the same antibody without that amino acid substitution in the Fc domain. Suitable methods for measuring ADCC are well known in the art (see, for example, PCT Publication No. WO 2006 / 082515 or PCT Publication No. WO 2012 / 130831).

[0114] As used herein, the terms “engineering,” “engineered,” and “engineered modification” are considered to include any manipulation of the peptide backbone or post-translational modification of naturally occurring or recombinant peptides or fragments thereof. Engineering modification includes modifications to the amino acid sequence, glycosylation patterns, or side chain groups of individual amino acids, as well as combinations of these methods.

[0115] As used herein, the term "amino acid mutation" encompasses amino acid substitution, deletion, insertion, and modification. Any combination of substitution, deletion, insertion, and modification can be performed to obtain a final construct, provided that the final construct possesses the desired characteristics, such as reduced binding to the Fc receptor or increased association with another peptide. Amino acid sequence deletions and insertions include deletions and insertions of the amino-terminus and / or carboxyl-terminus of amino acids. Preferred amino acid mutations are amino acid substitutions. Non-conservative amino acid substitutions, i.e., replacing an amino acid with another amino acid having a different structure and / or chemical properties, are particularly preferred for the purpose of altering, for example, the binding characteristics of the Fc region. Amino acid substitutions include substitution with non-naturally occurring amino acids or with naturally occurring amino acid derivatives of the twenty standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods well known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis, etc. Methods for altering amino acid side chain groups by means other than genetic engineering (such as chemical modification) are also considered useful. Various names may be used herein to refer to the same amino acid mutation. For example, replacing the proline at position 329 of the Fc domain with glycine can be represented as 329G, G329, G 329 P329G or Pro329Gly.

[0116] The "percentage of amino acid sequence identity (%)" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to those in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing vacancies (if necessary) to achieve the maximum percentage of sequence identity, without considering any conserved substitutions as part of the sequence identity. Alignment used to determine the percentage of amino acid sequence identity can be performed in various ways within the scope of the art, such as using publicly available computer software, such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software, or the FASTA package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment across the full length of the sequences being compared. Alternatively, the sequence comparison computer program ALIGN-2 can be used to generate the percentage of identity values. The ALIGN-2 sequence comparison computer program was written by Genentech, and the source code has been submitted with the user documentation to the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registry No. TXU510087 and described in WO 2001 / 007611.

[0117] Unless otherwise specified, for the purposes of this paper, amino acid sequence identity % values ​​were generated using the ggsearch program of FASTA package version 36.3.8c or later with the BLOSUM50 comparison matrix. The FASTA package was created by WRPearson and DJ Lipman, “Improved Tools for Biological Sequence Analysis”, PNAS 85 (1988): 2444-2448; WRPearson, “Effective protein sequence comparison”, Meth. Enzymol. 266 (1996): 227-258; and Pearson et al., (Genomics 46 (1997) 24-36) and is publicly available at www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, sequences can be compared using a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi, using the ggsearch (global protein: protein) program with default options (BLOSUM50; open: -10; ext: -2; Ktup=2) to ensure a global rather than local alignment. The percentage of amino acid identity is given in the output alignment header.

[0118] The terms "polynucleotide" or "nucleic acid molecule" include any compound and / or substance comprising a polymer of nucleotides. Each nucleotide consists of a base, particularly a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate ester group. Typically, nucleic acid molecules are described by a base sequence, where the bases represent the primary structure (linear structure) of the nucleic acid molecule. Base sequences are typically represented from 5' to 3'. In this document, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) (including, for example, complementary DNA (cDNA) and genomic DNA), ribonucleic acid (RNA) (particularly messenger RNA (mRNA)), synthetic forms of DNA or RNA, and mixed polymers containing two or more of these molecules. Nucleic acid molecules can be linear or circular. Furthermore, the term nucleic acid molecule includes sense and antisense strands, as well as single-stranded and double-stranded forms. Additionally, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases having derivatized sugar or phosphate backbone bonds or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct in vitro and / or in vivo (e.g., in a host or patient) expression of antibodies used in this invention. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and / or the expression of the encoding molecule, making it possible to inject mRNA into a subject to generate in vivo antibodies (see, for example, Stadler et al., (2017) Nature Medicine 23:815-817, or EP 2 101823 B1).

[0119] "Isolated" nucleic acid molecules refer to nucleic acid molecules that have been isolated from components of their natural environment. Isolated nucleic acid molecules include those contained in cells that normally contain said nucleic acid molecules, but which are located outside chromosomes or at chromosomal locations different from their natural chromosomal locations.

[0120] "Isolated polynucleotides (or nucleic acids) encoding antibodies" refers to one or more polynucleotide molecules that encode the heavy and light chains (or fragments thereof) of an antibody, including such polynucleotide molecules in a single or different vectors, and such polynucleotide molecules present at one or more locations in the host cell.

[0121] As used herein, the term "vector" refers to a nucleic acid molecule capable of carrying another nucleic acid linked to it. This term includes vectors that function as self-replicating nucleic acid structures, as well as vectors incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of the nucleic acid to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0122] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells in which exogenous nucleic acids have been introduced, including progeny of such cells. Host cells include “transformers” and “transformed cells,” which include primary transformed cells and progeny derived from said primary transformed cells, regardless of passage number. Progeny may not be identical to the nucleic acid contents of the parent cells and may contain mutations. This includes mutant progeny with the same function or biological activity as screened or selected in the original transformed cells. Host cells are any type of cell system that can be used to produce the antibodies of the present invention. Host cells include cultured cells, such as cultured mammalian cells, such as, to name just a few, HEK cells, CHO cells, BHK cells, NSO cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells, or hybridoma cells, yeast cells, insect cells, and plant cells, as well as cells contained in transgenic animals, transgenic plants, or cultured plant or animal tissues. In one aspect, the host cells of the present invention are eukaryotic cells, particularly mammalian cells. In one respect, the host cell is not a cell within the human body.

[0123] The terms “pharmaceutical composition” or “pharmaceutical formulation” refer to a formulation in which the bioactive ingredient contained therein is in a form in which the composition is bioactively effective and which does not contain any additional components that would have unacceptable toxicity to a subject to whom the composition will be administered.

[0124] "Pharmaceutical carrier" refers to a component in a pharmaceutical composition or formulation other than the active ingredient, which is non-toxic to the subject. Pharmaceutical carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0125] As used herein, “treatment” (and its grammatical variations) refers to an attempt to alter the natural course of a disease in the treated individual and is a clinical intervention that can be performed for prevention or may be performed during a clinicopathological process. The desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and mitigating or improving prognosis. In some aspects, the antibodies of this invention are used to delay the development of disease or slow its progression.

[0126] The “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., human and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). In some respects, the individual or subject is a human.

[0127] The “effective amount” of a pharmaceutical agent (such as a pharmaceutical composition) refers to the amount that is sufficient to effectively achieve the desired therapeutic or preventative outcome at the required dose for the required period of time.

[0128] The term "packaging insert" is used to refer to the instruction leaflet typically included in the commercial packaging of a therapeutic product, which contains information concerning the indications, usage, dosage, administration, combination therapy, contraindications, and / or warnings related to the use of such therapeutic products.

[0129] II. Compositions and Methods

[0130] This invention provides antibodies that bind to CD3, including multispecific antibodies that bind to both CD3 and a second antigen. These antibodies exhibit excellent binding and stability, combined with other properties advantageous for therapeutic applications, such as efficacy and safety, pharmacokinetics, and manufacturability. The antibodies of this invention can be used, for example, to treat diseases such as cancer.

[0131] A. Anti-CD3 antibody

[0132] In one aspect, the present invention provides an antibody that binds to CD3. In another aspect, a separated antibody that binds to CD3 is provided. In yet another aspect, the present invention provides an antibody that specifically binds to CD3. In some aspects, the anti-CD3 antibody retains more than about 90% of its binding activity relative to its CD3 binding activity after 2 weeks at pH 6 and -80°C, particularly more than about 95%, as determined by surface plasmon resonance (SPR).

[0133] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody includes a first antigen-binding domain, the first antigen-binding domain comprising...

[0134] (i) Heavy chain variable region (VH), which is selected from the group consisting of the following:

[0135] (a) VH, which includes the heavy chain complementarity determination region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4 and HCDR 3 of SEQ ID NO:10;

[0136] (b) VH, which includes HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4 and HCDR 3 of SEQ ID NO:12;

[0137] (c)VH, which includes HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5 and HCDR 3 of SEQ ID NO:9;

[0138] (d) VH, which includes HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11; or

[0139] (e)VH, which includes HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7 and HCDR 3 of SEQ ID NO:13;

[0140] as well as

[0141] (ii) Light chain variable region (VL) containing the light chain complementarity determination region (LCDR) of SEQ ID NO:20.

[0142] 1. LCDR 2 of SEQ ID NO:21 and LCDR 3 of SEQ ID NO:22.

[0143] In a preferred aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain, the first antigen-binding domain comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, the HCDR 2 of SEQ ID NO:4, and the HCDR 3 of SEQ ID NO:10, and the light chain variable region comprising the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:20, the LCDR 2 of SEQ ID NO:21, and the LCDR 3 of SEQ ID NO:22.

[0144] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, the HCDR 2 of SEQ ID NO:5, and the HCDR 3 of SEQ ID NO:9, and the light chain variable region comprising the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:20, the LCDR 2 of SEQ ID NO:21, and the LCDR 3 of SEQ ID NO:22.

[0145] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:3, the HCDR 2 of SEQ ID NO:7, and the HCDR 3 of SEQ ID NO:13, and the light chain variable region comprising the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:20, the LCDR 2 of SEQ ID NO:21, and the LCDR 3 of SEQ ID NO:22.

[0146] In one respect, the antibody is a humanized antibody. In another respect, the antigen-binding domain is a humanized antigen-binding domain (i.e., the antigen-binding domain of a humanized antibody). In another respect, VH and / or VL are humanized variable regions.

[0147] In one respect, VH and / or VL contain a receptor human framework, such as a human immunoglobulin framework or a human common framework.

[0148] In one aspect, VH comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) selected from the group consisting of: SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19. In one aspect, VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19. In one aspect, VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19. In one aspect, the VH contains an amino acid sequence that is at least about 98% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CD3. In some aspects, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in the amino acid sequences of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19. In some aspects, the substitution, insertion, or deletion occurs in a region outside the CDR (i.e., in the FR). In one aspect, VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19. Optionally, VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19, including post-translational modifications of that sequence.

[0149] In one aspect, the VL comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:23. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:23. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:23. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:23. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CD3. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:23 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:23. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:23, including post-translational modifications of that sequence.

[0150] In one aspect, VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19; and VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:23. In another aspect, VH comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19; and VL comprises the amino acid sequence of SEQ ID NO:23.

[0151] In a preferred aspect, VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:16, and VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:23. In one aspect, VH comprises the amino acid sequence of SEQ ID NO:16, and VL comprises the amino acid sequence of SEQ ID NO:23.

[0152] In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:15, and the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:23. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO:15, and the VL comprises the amino acid sequence of SEQ ID NO:23.

[0153] In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:19, and the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:23. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO:19, and the VL comprises the amino acid sequence of SEQ ID NO:23.

[0154] In another aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, the VH comprising an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19; and the VL comprising the amino acid sequence of SEQ ID NO:23.

[0155] In a preferred aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:16; and the VL comprises the amino acid sequence of SEQ ID NO:23.

[0156] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:15; and the VL comprises the amino acid sequence of SEQ ID NO:23.

[0157] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:19; and the VL comprises the amino acid sequence of SEQ ID NO:23.

[0158] In another aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising a VH sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19 and a VL sequence of SEQ ID NO:23.

[0159] In a preferred aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising the VH sequence of SEQ ID NO:16 and the VL sequence of SEQ ID NO:23.

[0160] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising the VH sequence of SEQ ID NO:15 and the VL sequence of SEQ ID NO:23.

[0161] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising the VH sequence of SEQ ID NO:19 and the VL sequence of SEQ ID NO:23.

[0162] In another aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, wherein the VH comprises a heavy chain CDR sequence of the VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19; and the VL comprises a light chain CDR sequence of the VL of SEQ ID NO:23.

[0163] In a preferred aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:16; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:23.

[0164] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, the VH comprising the heavy chain CDR sequence of VH of SEQ ID NO:15; and the VL comprising the light chain CDR sequence of VL of SEQ ID NO:23.

[0165] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising VH and VL, the VH comprising the heavy chain CDR sequence of VH of SEQ ID NO:19; and the VL comprising the light chain CDR sequence of VL of SEQ ID NO:23.

[0166] In another aspect, the first antigen-binding domain comprises the HCDR1, HCDR2, and HCDR3 amino acid sequences of VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19, and the LCDR1, LCDR2, and LCDR3 amino acid sequences of VL of SEQ ID NO:23.

[0167] In a preferred aspect, the first antigen-binding domain comprises the amino acid sequences HCDR1, HCDR2 and HCDR3 of VH in SEQ ID NO:16 and the amino acid sequences LCDR1, LCDR2 and LCDR3 of VL in SEQ ID NO:23.

[0168] In one aspect, the first antigen-binding domain comprises the amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH in SEQ ID NO:15 and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL in SEQ ID NO:23.

[0169] In one aspect, the first antigen-binding domain comprises the amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH in SEQ ID NO:19 and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL in SEQ ID NO:23.

[0170] In one aspect, VH comprises a heavy chain CDR sequence of VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19, and a frame sequence having at least 95%, 96%, 97%, 98%, or 99% sequence identity with a frame sequence of VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19. In another aspect, VH comprises a heavy chain CDR sequence of VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19, and a frame sequence having at least 95% sequence identity with a frame sequence of VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19. On the other hand, VH comprises the heavy chain CDR sequence of VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19, and a frame having at least 98% sequence identity with the frame sequence of VH selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19.

[0171] In a preferred aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:16, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of VH of SEQ ID NO:16. In one aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:16, and a frame, said frame having at least 95% sequence identity with the frame sequence of VH of SEQ ID NO:16. In another aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:16, and a frame, said frame having at least 98% sequence identity with the frame sequence of VH of SEQ ID NO:16.

[0172] In one aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:15, and a frame, said frame being at least 95%, 96%, 97%, 98%, or 99% sequence identical to the frame sequence of VH of SEQ ID NO:15. In another aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:15, and a frame, said frame being at least 95% sequence identical to the frame sequence of VH of SEQ ID NO:15. In yet another aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:15, and a frame, said frame being at least 98% sequence identical to the frame sequence of VH of SEQ ID NO:15.

[0173] In one aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:19, and a frame, said frame being at least 95%, 96%, 97%, 98%, or 99% sequence identical to the frame sequence of VH of SEQ ID NO:19. In another aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:19, and a frame, said frame being at least 95% sequence identical to the frame sequence of VH of SEQ ID NO:19. In yet another aspect, VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:19, and a frame, said frame being at least 98% sequence identical to the frame sequence of VH of SEQ ID NO:19.

[0174] In one aspect, VL comprises the light chain CDR sequence of VL of SEQ ID NO:23, and a frame, said frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of VL of SEQ ID NO:23. In another aspect, VL comprises the light chain CDR sequence of VL of SEQ ID NO:23, and a frame, said frame having at least 95% sequence identity with the frame sequence of VL of SEQ ID NO:23. In yet another aspect, VL comprises the light chain CDR sequence of VL of SEQ ID NO:23, and a frame, said frame having at least 98% sequence identity with the frame sequence of VL of SEQ ID NO:23.

[0175] In one aspect, the present invention provides an antibody that binds to CD3, wherein the antibody comprises a first antigen-binding domain comprising a VH sequence and a VL sequence, the VH sequence being as described in any of the aspects provided above, and the VL sequence being as described in any of the aspects provided above.

[0176] In one aspect, the antibody comprises a human constant region. In another aspect, the antibody is an immunoglobulin molecule comprising a human constant region, particularly an IgG-type immunoglobulin molecule comprising human CH1, CH2, CH3, and / or CL domains. Exemplary sequences of the human constant domains are given in SEQ ID NO:50 and SEQ ID NO:51 (human κ and λCL domains, respectively) and SEQ ID NO:52 (human IgG1 heavy chain constant domain CH1-CH2-CH3). In one aspect, the antibody comprises a light chain constant region comprising an amino acid sequence identical to that of SEQ ID NO:50 or SEQ ID NO:51, particularly the amino acid sequence of SEQ ID NO:50, which is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical. In one aspect, the antibody comprises a heavy chain constant region comprising an amino acid sequence identical to that of SEQ ID NO:52, which is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical. Specifically, the heavy chain constant region may contain amino acid mutations in the Fc domain as described herein.

[0177] In one aspect, the first antigen-binding domain comprises a human constant region. In another aspect, the first antigen-binding portion is a Fab molecule comprising a human constant region, particularly a human CH1 and / or CL domain. In one aspect, the first antigen-binding domain comprises a light chain constant region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50 or SEQ ID NO:51, particularly the amino acid sequence of SEQ ID NO:50. Specifically, the light chain constant region may comprise amino acid mutations under “charged modification” as described herein and / or, if in a cross-Fab molecule, may comprise deletions or substitutions of one or more (particularly two) N-terminal amino acids. In some aspects, the first antigen-binding domain comprises a heavy chain constant region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the CH1 domain sequence contained in the amino acid sequence of SEQ ID NO:52. Specifically, the heavy chain constant region (especially the CH1 domain) can contain amino acid mutations that are under “charged modification” as described in this paper.

[0178] In one respect, the antibody is a monoclonal antibody.

[0179] In one respect, antibodies are IgG, especially IgG1 antibodies. In another respect, antibodies are full-length antibodies.

[0180] On the other hand, the antibody is an antibody fragment selected from Fv molecules, scFv molecules, Fab molecules, and F(ab')2 molecules; especially Fab molecules. On the other hand, the antibody fragment is a disomic antibody, a trisomic antibody, or a tetrasomic antibody.

[0181] In one aspect, the first antigen-binding domain is a Fab molecule. In a preferred aspect, the first antigen-binding domain is a Fab molecule, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are interchanged with each other or the constant domains CL and CH1 are interchanged with each other, particularly the variable domains VL and VH are interchanged with each other (i.e., the first antigen-binding domain is a cross-Fab molecule).

[0182] On the other hand, the antibody according to any one of the foregoing aspects may be combined, alone or in combination, with the features described in Part II A.1.-8 below.

[0183] In a preferred aspect, the antibody comprises an Fc domain, particularly an IgG Fc domain, and more particularly an IgG1 Fc domain. In one aspect, the Fc domain is a human Fc domain. In another aspect, the Fc domain is an IgG1 Fc domain. The Fc domain is composed of a first subunit and a second subunit, and may incorporate, alone or in combination, any of the features described below with respect to Fc domain variants (Section II. A.8.).

[0184] In another preferred aspect, the antibody comprises a second antigen-binding domain that binds to the second antigen and optionally a third antigen-binding domain (i.e., the antibody is a multispecific antibody, as described further below in (Section II A.7.)).

[0185] 1. Antibody fragments

[0186] In some respects, the antibodies presented in this article are antibody fragments.

[0187] In one respect, antibody fragments are Fab', Fab'-SH, or F(ab')2 molecules, particularly Fab molecules as described herein. A “Fab' molecule” differs from a Fab molecule in that the Fab' fragment has residues added to the carboxyl terminus of the CH1 domain, including one or more cysteine ​​residues from the antibody hinge region. Fab'-SH is a Fab' molecule in which the cysteine ​​residues in the constant domain have free thiol groups. Pepsin treatment produces F(ab')2 molecules, which have two antigen-binding sites (two Fab molecules) and a portion of the Fc region.

[0188] On the other hand, antibody fragments are bisomatic, trisomatic, or tetrasomatic antibodies. A “bisomatic antibody” is an antibody fragment having two antigen-binding sites, which can be bivalent or bispecific. See, for example, EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Trisomatic and tetrasomatic antibodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0189] In another aspect, the antibody fragment is a single-chain Fab molecule. A “single-chain Fab molecule” or “scFab” is a polypeptide composed of an antibody heavy chain variable domain (VH), an antibody heavy chain constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, wherein the antibody domains and the linker have one of the following sequences in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL. Specifically, the linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. The single-chain Fab molecule is stabilized via a native disulfide bond between the CL domain and the CH1 domain. Furthermore, these single-chain Fab molecules can be further stabilized by generating interchain disulfide bonds via the insertion of cysteine ​​residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0190] On the other hand, the antibody fragment is a single-chain variable fragment (scFv). A "single-chain variable fragment" or "scFv" is a fusion protein of the antibody's heavy chain variable domain (VH) and light chain variable domain (VL), linked by a linker. Specifically, the linker is a short polypeptide of approximately 10 to 25 amino acids, typically rich in glycine for flexibility and serine or threonine for solubility, and can link the N-terminus of the VH to the C-terminus of the VL, or vice versa. Despite the removal of the constant region and the introduction of the linker, the protein retains the specificity of the original antibody. For reviews of scFv fragments, see, for example, Plückthun, in The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Rosenburg and Moore (Springer-Verlag, New York), pp. 269–315 (1994); see also WO 93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458.

[0191] On the other hand, antibody fragments are single-domain antibodies. A "single-domain antibody" is an antibody fragment containing all or part of the variable heavy chain domain or all or part of the variable light chain domain of an antibody. In some respects, single-domain antibodies are human single-domain antibodies (Domantis, Inc., Waltham, MA; see, for example, U.S. Patent No. 6,248,516B1).

[0192] Antibody fragments can be prepared using various techniques, including but not limited to the proteolytic digestion of intact antibodies and recombinant production from recombinant host cells (e.g., E. coli), as described herein.

[0193] 2. Humanized antibodies

[0194] In some respects, the antibodies presented herein are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity in humans while retaining the specificity and affinity of the parent non-human antibody. Generally, humanized antibodies contain one or more variable domains, wherein the CDR (or a portion thereof) is derived from the non-human antibody, and the FR (or a portion thereof) is derived from the human antibody sequence. Humanized antibodies may also optionally contain at least a portion of the human constant region. In some respects, some FR residues in the humanized antibody are substituted with corresponding residues from the non-human antibody (e.g., the antibody from which the CDR residues are derived), for example, to restore or improve antibody specificity or affinity.

[0195] Humanized antibodies and their preparation methods are reviewed, for example, in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described, for example, in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); US Patent Nos. 5,821,337, 7,527,791, 6,982,321 and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describes specificity-determining region (SDR) transplantation); Padlan, Mol. Immunol. 28:489-498 (1991) (describes “surface remodeling”); Dall'Acqua et al., Methods 36:43-60 (2005) (describes “FR reorganization”); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br.J. Cancer, 83:252-260 (2000) (describes a “guided selection” approach for FR reorganization).

[0196] Human structural regions that can be used for humanization include, but are not limited to: structural regions selected using a “best fit” method (see, for example, Sims et al., J. Immunol. 151:2296 (1993)); structural regions of the common sequence of human antibodies derived from specific subgroups of light or heavy chain variable regions (see, for example, Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al., J. Immunol., 151:2623 (1993)). 3)); human mature (somatic mutation) architecture region or human germline architecture region (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and architecture regions derived from screened FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).

[0197] 3. Glycosylation variants

[0198] In some respects, the antibodies presented herein can be modified to increase or decrease the degree of antibody glycosylation. The addition or deletion of glycosylation sites to antibodies can be conveniently achieved by altering the amino acid sequence to create or remove one or more glycosylation sites.

[0199] When an antibody contains an Fc region, the oligosaccharide associated with it can be modified. Natural antibodies produced by mammalian cells typically contain branched, biantennary oligosaccharides, which are typically linked via N-bonds to Asn297 of the CH2 domain of the Fc region. See, for example, Wright et al., TIBTECH 15:26-32 (1997). Oligosaccharides can include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose of GlcNAc attached to the “backbone” of the biantennary oligosaccharide structure. In some aspects, the oligosaccharides in the antibodies of the present invention can be modified to produce antibody variants with certain improved properties.

[0200] On the one hand, antibody variants with unfucosylated oligosaccharides are provided, i.e., oligosaccharide structures lacking (directly or indirectly) fucose linked to the Fc region. Such unfucosylated oligosaccharides (also known as "defucosylated" oligosaccharides) are particularly N-linked oligosaccharides that lack the fucose residues linking the first GlcNAc in the stem of the biantennary oligosaccharide structure. On the other hand, antibody variants with an increased proportion of unfucosylated oligosaccharides in the Fc region compared to natural or parental antibodies are provided. For example, the proportion of unfucosylated oligosaccharides can be at least about 20%, at least about 40%, at least about 60%, at least about 80%, or even about 100% (i.e., no fucose-linked oligosaccharides present). The percentage of non-fucosylated oligosaccharides, as described, for example, in WO2006 / 082515, and as measured by MALDI-TOF mass spectrometry, is the (average) amount of oligosaccharides lacking fucose residues relative to the sum of all oligosaccharides (e.g., complex, heterozygous, and high-mannose structures) linked to Asn 297. Asn297 refers to the asparagine residue (EU number of Fc region residues) located at approximately position 297 in the Fc region; however, due to minor sequence variations in antibodies, Asn297 can also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such antibodies with an increased proportion of non-fucosylated oligosaccharides in the Fc region may exhibit improved FcγRIIIa receptor binding and / or improved effector function, particularly improved ADCC function. See, for example, US 2003 / 0157108 and US 2004 / 0093621.

[0201] Examples of cell lines capable of producing antibodies with reduced fucosylation include Lec13 CHO cells lacking protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US 2003 / 0157108; and WO 2004 / 056312, especially in Example 11), and knockout cell lines, such as those with the α-1,6-fucosylation gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87:614-622 (2004); Kanda, Y. et al. Biotechnol. Bioeng. 94(4):680-688 (2006); and WO 2003 / 085107), or cells with reduced or eliminated GDP-fucose synthesis or transporter activity (see, for example, US2004259150, US2005031613, US2004132140, US2004110282).

[0202] On the other hand, antibody variants provide bipartite oligosaccharides, for example, wherein biantennary oligosaccharides linked to the Fc region of the antibody are bipartitely divided by GlcNAc. As described above, such antibody variants can have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in Umana et al., Nat Biotechnol 17, 176-180 (1999); Ferrara et al., Biotechn Bioeng 93, 851-861 (2006); WO 99 / 54342; WO 2004 / 065540, WO 2003 / 011878.

[0203] Antibody variants having at least one galactose residue in the oligosaccharide linked to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087, WO 1998 / 58964 and WO 1999 / 22764.

[0204] 4. Cysteine ​​engineered antibody variants

[0205] In some respects, it may be necessary to produce cysteine-engineered antibodies, such as THIOMAB. TMAn antibody in which one or more residues of the antibody are substituted with cysteine ​​residues. In a preferred aspect, the substituted residues are located at an accessible site of the antibody. As further described herein, by substituting those residues with cysteine, a reactive thiol group is positioned at an accessible site of the antibody and can be used to conjugate the antibody with other parts, such as a pharmaceutical part or a linker-pharmaceutical part, to produce an immunoconjugate. Cysteine-engineered antibodies can be produced, for example, as described in U.S. Patent Nos. 7,521,541, 8,30,930, 7,855,275, 9,000,130, or WO 2016040856.

[0206] 5. Antibody derivatives

[0207] In some respects, the antibodies provided herein can be further modified to contain additional non-protein moieties known in the art and readily available. Suitable moieties for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol / propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homogeneous or random copolymers) and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethyleneized polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. PEG-propionaldehyde may be advantageous in manufacturing due to its stability in water. The polymers can have any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. Typically, the number and / or type of polymers used for derivatization can be determined based on the following considerations, including but not limited to the specific properties or functions of the antibody to be improved, and whether the antibody derivative will be used for a limited therapy.

[0208] 6. Immunoconjugates

[0209] The present invention also provides immunoconjugates comprising the anti-CD3 antibody described herein, which is conjugated (chemically bonded) to one or more therapeutic agents, such as cytotoxic agents, chemotherapeutic agents, drugs, growth inhibitors, toxins (e.g., protein toxins, bacterial, fungal, plant or animal-derived enzyme-active toxins or fragments thereof) or radioisotopes.

[0210] On the one hand, immunoconjugates are antibody-drug conjugates (ADCs), in which an antibody is conjugated to one or more therapeutic agents. A linker is typically used to connect the antibody to one or more therapeutic agents. An overview of ADC technology is provided in Pharmacol Review 68:3-19 (2016), which includes examples of therapeutic agents, drugs, and linkers.

[0211] On the other hand, the immunoconjugate comprises the antibody of the present invention conjugated to an enzyme-active toxin or a fragment thereof, said enzyme-active toxin or fragment thereof including but not limited to diphtheria A chain, non-conjugated active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, absinthecin A chain, sarcin, tung oil protein, dianthin protein, Phytolaca americana protein (PAPI, PAPII and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelatin, mitogellin, localized aspergillin, phenolmycin, enomycin, and trichothecenes.

[0212] On the other hand, immunoconjugates include antibodies of the present invention conjugated with radioactive atoms to form radioconjugates. A variety of radioisotopes can be used to produce radioconjugates. Examples include At... 211 I 131 I 125 Y 90 Re 186 Re 188 、Sm 153 Bi 212 P 32 Pb 212 Radioactive isotopes of Lu. When radioconjugates are used for detection, they may contain radioactive atoms used in scintillation studies, such as Tc. 99m or I 123 Or spin markers used in magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as I 123 I 131 In 111 F 19 C 13 N 15 O 17 Gadolinium, manganese, or iron.

[0213] A variety of bifunctional protein conjugates, such as N-succinimino-3-(2-pyridyldithio)propionate (SPDP), succinimino-4-(N-maleiminomethyl)cyclohexane-1-carboxylic acid succinimide ester (SMCC), iminothiacyclopentane (IT), bifunctional derivatives of imino esters (such as dimethyl adipate hydrochloride), active esters (such as disuccinimino octanoate), aldehydes (such as glutaraldehyde), diazid compounds (such as bis(p-azidobenzoyl)hexamethylenediamine), diazido derivatives (such as bis-(p-diazobenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and difluorinated compounds (such as 1,5-difluoro-2,4-dinitrobenzene), can be used to prepare conjugates of antibodies and cytotoxic agents. For example, ricin immunotoxin can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14 labeled 1-isothiocyanobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radioactive nucleotides to antibodies. See WO 94 / 11026. The adapter can be a “cleavable adapter” that promotes the release of cytotoxic drugs from cells. For example, acid-labile adapters, peptidase-sensitive adapters, light-labile adapters, dimethyl adapters, or disulfide-containing adapters can be used (Chari et al., Cancer Res. 52:127-131 (1992); US Patent No. 5,208,020).

[0214] The immunoconjugates or ADCs described herein are explicitly considered, but not limited to, such conjugates prepared with cross-linking agents, including but not limited to commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., USA) BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfon-EMCS, sulfon-GMBS, sulfon-KMUS, sulfon-MBS, sulfon-SIAB, sulfon-SMCC, sulfon-SMPB, and SVSB (succinimino-(4-vinyl sulfone)benzoate).

[0215] 7. Multispecific antibodies

[0216] In some respects, the antibodies provided herein are multispecific antibodies, particularly bispecific antibodies. A multispecific antibody is a monoclonal antibody that has binding specificity to at least two different antigenic determinants (e.g., two different proteins, or two different epitopes on the same protein). In some respects, a multispecific antibody has three or more binding specificities. In some respects, one of the binding specificities is against CD3, and another specificity is against any other antigen. In some respects, a multispecific antibody can bind to two (or more) different epitopes of CD3. Multispecific (e.g., bispecific) antibodies can also be used to target cytotoxic agents or cells to cells expressing CD3. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0217] Techniques for preparing multispecific antibodies include, but are not limited to, recombinant co-expression of heavy-light chain pairs of two immunoglobulins with different specificities (see Milstein and Cuello, Nature 305:537 (1983)) and engineered “mortar and pestle structures” (see, for example, U.S. Patent 5,731,168 and Atwell et al., J.Mol.Biol.270:26 (1997)). Multispecific antibodies can also be prepared by: engineering electrostatic manipulation effects used to prepare antibody Fc-heterodimer molecules (see, for example, WO 2009 / 089004); crosslinking two or more antibodies or fragments (see, for example, U.S. Patent No. 4,676,980, and Brennan et al., Science, 229:81 (1985)); using leucine zippers to generate bispecific antibodies (see, for example, Kostelny et al., J. Immunol., 148(5):1547-1553 (1992) and WO 2011 / 034605); using common light chain techniques to avoid light chain mismatch problems (see, for example, WO 98 / 50431); using the “dimeric antibody” technique for preparing bispecific antibody fragments (see, for example, Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv(sFv) dimers (see, for example, Gruber et al., J. Immunol., 152:5368 (1994)); and preparing trispecific antibodies as described in Tutt et al., J. Immunol. 147:60 (1991).

[0218] This document also includes engineered antibodies having three or more antigen-binding sites, including, for example, “octopus antibodies” or DVD-Ig (see, for example, WO 2001 / 77342 and WO 2008 / 024715). Other examples of multispecific antibodies having three or more antigen-binding sites can be found in WO 2010 / 115589, WO 2010 / 112193, WO 2010 / 136172, WO 2010 / 145792 and WO 2013 / 026831. Multispecific antibodies or their antigen-binding fragments also include “dual-acting FAbs” or “DAFs” that contain antigen-binding sites that bind to CD3 and another different antigen or to two different epitopes of CD3 (see, for example, US 2008 / 0069820 and WO 2015 / 095539).

[0219] Multispecific antibodies can also be provided asymmetrically, wherein there is domain crossover in one or more binding arms having the same antigen specificity (so-called "CrossMab" technology), i.e., by exchanging VH / VL domains (see, for example, WO 2009 / 080252 and WO 2015 / 150447), CH1 / CL domains (see, for example, WO 2009 / 080253), or the complete Fab arm (see, for example, WO 2009 / 080251, WO 2016 / 016299, and also Schaefer et al., PNAS, 108(2011) 1187-1191, and Klein et al., MAbs 8(2016) 1010-20). Asymmetric Fab arms can also be engineered by introducing charged or uncharged amino acid mutations into the domain interfaces to guide the correct Fab pairing. See, for example, WO 2016 / 172485.

[0220] Various other molecular forms of multispecific antibodies are known in the art and are included herein (see, for example, Spiess et al., Mol Immunol 67 (2015) 95-106).

[0221] This document also includes a specific type of multispecific antibody, which is a bispecific antibody designed to simultaneously bind to a surface antigen on a target cell (e.g., a tumor cell) and an activation-invariant component of the T-cell receptor (TCR) complex (such as CD3) for retargeting T cells to kill the target cell. Therefore, in a preferred aspect, the antibodies provided herein are multispecific antibodies, particularly bispecific antibodies, wherein one binding specificity targets CD3 while the other targets a target cell antigen.

[0222] Examples of bispecific antibody forms that can be used for this purpose include, but are not limited to: so-called “BiTE” (bispecific T-cell recruiter) molecules, in which two scFv molecules are fused via a flexible linker (see, for example, WO 2004 / 106381; WO2005 / 061547; WO 2007 / 042261; WO 2008 / 119567; Nagorsen and Exp Cell Res 317, 1255-1260 (2011)); bisomatic antibodies (Holliger et al., Prot Eng 9, 299-305 (1996)) and their derivatives, such as tandem bisomatic antibodies (“TandAb”; Kipriyanov et al., J Mol Biol 293, 41-56 (1999)); “DART” (biaffinity retargeting) molecules, which are based on bisomatic antibody forms but have C-terminal disulfide bonds for additional stabilization (Johnson et al., J Mol Biol 399, 436-449 (2010)); and so-called trifunctional antibodies, which are complete hybrid mouse / rat IgG molecules (as reviewed by Seimetz et al.: Cancer Treat Rev 36, 458-467 (2010)). The specific forms of T-cell bispecific antibodies described in this article are described in the following references: WO 2013 / 026833; WO 2013 / 026839; WO 2016 / 020309; Bacac et al., Oncoimmunology 5(8)(2016)e1203498.

[0223] Preferred aspects of the multispecific antibody of the present invention are described below.

[0224] In one aspect, the present invention provides an antibody that binds to CD3, comprising a first antigen-binding domain as described herein that binds to CD3, and a second antigen-binding domain that binds to a second antigen and optionally a third antigen-binding domain.

[0225] According to a preferred aspect of the invention, the antigen-binding domain contained in the antibody is a Fab molecule (i.e., an antigen-binding domain composed of a heavy chain and a light chain, each antigen-binding domain comprising a variable domain and a constant domain). In one aspect, the first antigen-binding domain, the second antigen-binding domain, and / or the third antigen-binding domain, in the presence of the first, second, and / or third antigen-binding domains, are Fab molecules. In one aspect, the Fab molecule is human. In a preferred aspect, the Fab molecule is humanized. In another aspect, the Fab molecule comprises human heavy chain and light chain constant domains.

[0226] Preferably, at least one of the antigen-binding domains is a cross-Fab molecule. This modification reduces mismatches between the heavy and light chains from different Fab molecules, thereby improving the yield and purity of the (multispecific) antibody of the present invention in recombinant production. In preferred cross-Fab molecules that can be used to contain the (multispecific) antibody of the present invention, the variable domains (VL and VH, respectively) of the Fab light chain and Fab heavy chain are exchanged. However, even with this domain exchange, the preparation of the (multispecific) antibody may contain certain byproducts due to the so-called Bence Jones-type interaction between the mismatched heavy and light chains (see Schaefer et al., PNAS, 108(2011) 11187-11191). To further reduce heavy and light chain mismatches from different Fab molecules and thereby improve the purity and yield of the desired (multispecific) antibody, charged amino acids with opposite charges can be introduced at specific amino acid positions in the CH1 and CL domains of either the Fab molecule that binds to the first antigen (CD3) or the Fab molecule that binds to the second antigen (e.g., target cell antigens such as TYRP-1, CEA, GPRC5D, or CD19), as further described herein. In conventional Fab molecules contained in (multispecific) antibodies (such as, for example, in...), Figure 1 A to Figure 1 C Figure 1 G to Figure 1 (as shown in J) or in VH / VL cross-Fab molecules contained in (multispecific) antibodies (such as, for example, in Figure 1 D to Figure 1 F, Figure 1 K to Figure 1 The charge modification is performed (as shown in N) (but not in either of them). In a preferred aspect, the charge modification is performed in a conventional Fab molecule contained in a (multispecific) antibody (in a preferred aspect, with a second antigen, such as a target cell antigen, such as TYRP-1, CEA, GPRC5D, or CD19).

[0227] In a preferred aspect of the invention, the (multispecific) antibody is capable of simultaneously binding to a first antigen (i.e., CD3) and a second antigen (e.g., a target cell antigen, such as TYRP-1, CEA, GPRC5D, or CD19). In one aspect, the (multispecific) antibody is capable of cross-linking T cells and target cells by simultaneously binding to CD3 and the target cell antigen. In an even more preferred aspect, this simultaneous binding leads to the lysis of target cells, particularly tumor cells expressing the target cell antigen (e.g., TYRP-1, CEA, GPRC5D, or CD19). In one aspect, this simultaneous binding leads to the activation of T cells. In other aspects, this simultaneous binding leads to a cellular response of T lymphocytes, particularly cytotoxic T lymphocytes, selected from: proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. In one aspect, the (multispecific) antibody binding to CD3 without simultaneously binding to the target cell antigen does not lead to T cell activation.

[0228] In one aspect, (multispecific) antibodies can redirect the cytotoxic activity of T cells to target cells. In a preferred aspect, this redirection is independent of MHC-mediated peptide antigen presentation by the target cells and / or T cell specificity.

[0229] Preferably, the T cells according to any aspect of the invention are cytotoxic T cells. In some aspects, the T cells are CD4+ cells. + or CD8 + T cells, especially CD8 + T cells.

[0230] a) First antigen-binding domain

[0231] The (multispecific) antibody of the present invention comprises at least one antigen-binding domain (first antigen-binding domain) that binds to CD3. In a preferred aspect, CD3 is human CD3 (SEQ ID NO:45) or cynomolgus monkey CD3 (SEQ ID NO:46), most particularly human CD3. In one aspect, the first antigen-binding domain cross-reacts (i.e., specifically binds) to human and cynomolgus monkey CD3. In some aspects, CD3 is the ε subunit of CD3 (CD3ε).

[0232] In one preferred aspect, the (multispecific) antibody comprises no more than one antigen-binding domain that binds to CD3. In another aspect, the (multispecific) antibody provides monovalent binding to CD3.

[0233] In one aspect, the antigen-binding domain that binds to CD3 is an antibody fragment selected from the group consisting of Fv molecules, scFv molecules, Fab molecules, and F(ab')2 molecules. In a preferred aspect, the antigen-binding domain that binds to CD3 is a Fab molecule.

[0234] In a preferred aspect, the antigen-binding domain binding to CD3 is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy and light chains are exchanged / replaced with each other, or the constant domains CH1 and CL are exchanged / replaced with each other. In this respect, the antigen-binding domain binding to a second antigen (e.g., a target cell antigen, such as TYRP-1, CEA, GPRC5D, or CD19) is preferably a conventional Fab molecule. In (multispecific) antibodies, there are more than one antigen-binding domain binding to a second antigen, particularly in the Fab molecule aspect; the antigen-binding domain binding to CD3 is preferably a cross-Fab molecule, and the antigen-binding domain binding to the second antigen is a conventional Fab molecule.

[0235] In alternatives, the antigen-binding domain that binds to CD3 is a conventional Fab molecule. In this respect, the antigen-binding domain that binds to a second antigen (e.g., a target cell antigen such as TYRP-1, CEA, GPRC5D, or CD19) is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy and light chains exchange / replace each other, or the constant domains CH1 and CL exchange / replace each other. In (multispecific) antibodies, there are more than one CD3-binding antigen-binding domain, particularly in the Fab molecule aspect; the antigen-binding domain binding to the second antigen is preferably a cross-Fab molecule, while the CD3-binding antigen-binding domain is a conventional Fab molecule.

[0236] In a preferred aspect, the first antigen-binding domain is a Fab molecule, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are interchanged, or the constant domains CL and CH1 are interchanged, particularly the variable domains VL and VH (i.e., according to such an aspect, the first antigen-binding domain is a cross-Fab molecule, wherein the variable or constant domains of the Fab light chain and the Fab heavy chain are exchanged). In one such aspect, the second (and third, if any) antigen-binding domain is a conventional Fab molecule.

[0237] In one respect, (multispecific) antibodies contain no more than one antigen-binding domain that binds to CD3 (i.e., the antibody provides monovalent binding to CD3).

[0238] b) Second (and third) antigen-binding domains

[0239] In some aspects, the (multispecific) antibody of the present invention comprises at least one antigen-binding domain, particularly a Fab molecule, that binds to a second antigen. The second antigen is preferably not CD3, i.e., different from CD3. In one aspect, the second antigen is an antigen expressed on cells different from CD3 (e.g., expressed on cells other than T cells). In one aspect, the second antigen is a target cell antigen, particularly a tumor cell antigen. In a specific aspect, the second antigen is TYRP-1. In another specific aspect, the second antigen is CEA. In yet another specific aspect, the second antigen is GPRC5D. In yet another specific aspect, the second antigen is CD19. The second antigen-binding domain is capable of directing the (multispecific) antibody to a target site, for example, to a specific type of tumor cell expressing the second antigen.

[0240] In one aspect, the antigen-binding domain binding to the second antigen is an antibody fragment selected from the group consisting of Fv molecules, scFv molecules, Fab molecules, and F(ab')2 molecules. In a preferred aspect, the antigen-binding domain binding to the second antigen is a Fab molecule.

[0241] In some respects, (multispecific) antibodies comprise two antigen-binding domains, particularly Fab molecules, that bind to a second antigen. In a preferred embodiment of this, each of these antigen-binding domains binds to the same antigenic determinant. In an even more preferred embodiment, all these antigen-binding domains are preferably identical, i.e., they have the same molecular form (e.g., conventional or cross-cut Fab molecules) and contain the same amino acid sequence (including the same amino acid substitutions in the CH1 and CL domains, as described herein (if any)). In one embodiment, (multispecific) antibodies comprise no more than two antigen-binding domains, particularly Fab molecules, that bind to a second antigen.

[0242] In a preferred aspect, the antigen-binding domain binding to the second antigen is a conventional Fab molecule. In this respect, the antigen-binding domain binding to CD3 is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy and light chains exchange / replace each other, or the constant domains CH1 and CL exchange / replace each other.

[0243] In alternatives, the antigen-binding domain binding to the second antigen is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL of the Fab heavy and light chains exchange / replace each other, or the constant domains CH1 and CL exchange / replace each other. In this respect, the antigen-binding domain binding to CD3 is a conventional Fab molecule.

[0244] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) comprises a human constant region. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a Fab molecule comprising a human constant region, particularly a human CH1 and / or CL domain. Exemplary sequences of the human constant domain are given in SEQ ID NO:50 and SEQ ID NO:51 (human κ and λCL domains, respectively) and SEQ ID NO:52 (human IgG1 heavy chain constant domain CH1-CH2-CH3). In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) comprises a light chain constant region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO:50 or SEQ ID NO:51, particularly the amino acid sequence of SEQ ID NO:50. Specifically, the light chain constant region may contain amino acid mutations under “charged modification” as described herein and / or, in the case of a cross-Fab molecule, may contain deletions or substitutions of one or more (particularly two) N-terminal amino acids. In some aspects, the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises a heavy chain constant region containing an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the CH1 domain sequence contained in the amino acid sequence of SEQ ID NO:52. Specifically, the heavy chain constant region (particularly the CH1 domain) may contain amino acid mutations under “charged modification” as described herein.

[0245] In some respects, the second antigen is TYRP-1, especially human TYRP-1.

[0246] In one aspect, the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:24, the HCDR 2 of SEQ ID NO:25, and the HCDR 3 of SEQ ID NO:26; the light chain variable region comprising the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:28, the LCDR 2 of SEQ ID NO:29, and the LCDR 3 of SEQ ID NO:30.

[0247] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is derived from a humanized antibody. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a humanized antigen-binding domain (i.e., the antigen-binding domain of the humanized antibody). In yet another aspect, the VH and / or VL of the second antigen-binding domain (and, if present, the third antigen-binding domain) are humanized variable regions.

[0248] In one aspect, the VH and / or VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) contain a receptor human frame, such as the human immunoglobulin frame or the human common frame.

[0249] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO:27. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:27. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:27. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:27. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to TYRP-1. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:27 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, VH comprises the amino acid sequence of SEQ ID NO:27. Optionally, VH comprises the amino acid sequence of SEQ ID NO:27, including post-translational modifications of that sequence.

[0250] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:31. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:31. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:31. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:31. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to TYRP-1. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:31 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:31. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:31, including post-translational modifications of that sequence.

[0251] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:27, and the VL of the second antigen-binding domain comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:31. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO:27, and the VL comprises the amino acid sequence of SEQ ID NO:31.

[0252] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:27; and the VL comprises the amino acid sequence of SEQ ID NO:31.

[0253] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:31.

[0254] On the other hand, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:27; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:31.

[0255] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the HCDR1, HCDR2 and HCDR3 amino acid sequences of VH in SEQ ID NO:27 and the LCDR1, LCDR2 and LCDR3 amino acid sequences of VL in SEQ ID NO:31.

[0256] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the heavy chain CDR sequence of the VH of SEQ ID NO:27, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VH of SEQ ID NO:27. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:27, and a frame having at least 95% sequence identity with the frame sequence of the VH of SEQ ID NO:27. In yet another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:27, and a frame having at least 98% sequence identity with the frame sequence of the VH of SEQ ID NO:27.

[0257] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the light chain CDR sequence of the VL of SEQ ID NO:31, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VL of SEQ ID NO:31. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:31, and a frame having at least 95% sequence identity with the frame sequence of the VL of SEQ ID NO:31. In yet another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:31, and a frame having at least 98% sequence identity with the frame sequence of the VL of SEQ ID NO:31.

[0258] In some respects, the second antigen is CEA, especially human CEA.

[0259] In one aspect, the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:53, the HCDR 2 of SEQ ID NO:54, and the HCDR 3 of SEQ ID NO:55; the light chain variable region comprising the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:57, the LCDR 2 of SEQ ID NO:58, and the LCDR 3 of SEQ ID NO:59.

[0260] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is derived from a humanized antibody. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a humanized antigen-binding domain (i.e., the antigen-binding domain of the humanized antibody). In yet another aspect, the VH and / or VL of the second antigen-binding domain (and, if present, the third antigen-binding domain) are humanized variable regions.

[0261] In one aspect, the VH and / or VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) contain a receptor human frame, such as the human immunoglobulin frame or the human common frame.

[0262] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO:56. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:56. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:56. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:56. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identical contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CEA. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:56 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, VH comprises the amino acid sequence of SEQ ID NO:56. Optionally, VH comprises the amino acid sequence of SEQ ID NO:56, including post-translational modifications of that sequence.

[0263] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:60. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:60. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:60. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:60. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identical contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CEA. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:60 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:60. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:60, including post-translational modifications of that sequence.

[0264] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:56, and the VL of the second antigen-binding domain comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:60. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO:56, and the VL comprises the amino acid sequence of SEQ ID NO:60.

[0265] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:56; and the VL comprises the amino acid sequence of SEQ ID NO:60.

[0266] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the VH sequence of SEQ ID NO:56 and the VL sequence of SEQ ID NO:60.

[0267] On the other hand, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:56; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:60.

[0268] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the HCDR1, HCDR2 and HCDR3 amino acid sequences of VH in SEQ ID NO:56 and the LCDR1, LCDR2 and LCDR3 amino acid sequences of VL in SEQ ID NO:60.

[0269] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the heavy chain CDR sequence of the VH of SEQ ID NO:56, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VH of SEQ ID NO:56. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:56, and a frame having at least 95% sequence identity with the frame sequence of the VH of SEQ ID NO:56. In yet another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:56, and a frame having at least 98% sequence identity with the frame sequence of the VH of SEQ ID NO:56.

[0270] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the light chain CDR sequence of the VL of SEQ ID NO: 60, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VL of SEQ ID NO: 60. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 60, and a frame having at least 95% sequence identity with the frame sequence of the VL of SEQ ID NO: 60. In yet another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO: 60, and a frame having at least 98% sequence identity with the frame sequence of the VL of SEQ ID NO: 60.

[0271] On the other hand, the second antigen is CEA, particularly human CEA, and the second antigen-binding domain (and the third antigen-binding domain, if present) comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:105, HCDR 2 of SEQ ID NO:106, and HCDR 3 of SEQ ID NO:107. The light chain variable region comprises the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:109, LCDR 2 of SEQ ID NO:110, and LCDR 3 of SEQ ID NO:111.

[0272] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is derived from a humanized antibody. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a humanized antigen-binding domain (i.e., the antigen-binding domain of the humanized antibody). In yet another aspect, the VH and / or VL of the second antigen-binding domain (and, if present, the third antigen-binding domain) are humanized variable regions.

[0273] In one aspect, the VH and / or VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) contain a receptor human frame, such as the human immunoglobulin frame or the human common frame.

[0274] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO:108. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:108. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:108. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:108. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identical contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CEA. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:108 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, VH comprises the amino acid sequence of SEQ ID NO:108. Optionally, VH comprises the amino acid sequence of SEQ ID NO:108, including post-translational modifications of that sequence.

[0275] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:112. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:112. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:112. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:112. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identical contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CEA. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:112 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:112. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:112, including post-translational modifications of that sequence.

[0276] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO: 108, and the VL of the second antigen-binding domain comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO: 112. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO: 108, and the VL comprises the amino acid sequence of SEQ ID NO: 112.

[0277] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:108; and the VL comprises the amino acid sequence of SEQ ID NO:112.

[0278] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the VH sequence of SEQ ID NO:108 and the VL sequence of SEQ ID NO:112.

[0279] On the other hand, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:108; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:112.

[0280] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the amino acid sequences of HCDR1, HCDR2 and HCDR3 of VH in SEQ ID NO:108 and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL in SEQ ID NO:112.

[0281] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the heavy chain CDR sequence of the VH of SEQ ID NO:108, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VH of SEQ ID NO:108. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:108, and a frame having at least 95% sequence identity with the frame sequence of the VH of SEQ ID NO:108. In yet another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:108, and a frame having at least 98% sequence identity with the frame sequence of the VH of SEQ ID NO:108.

[0282] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the light chain CDR sequence of the VL of SEQ ID NO:112, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VL of SEQ ID NO:112. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:112, and a frame having at least 95% sequence identity with the frame sequence of the VL of SEQ ID NO:112. In yet another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:112, and a frame having at least 98% sequence identity with the frame sequence of the VL of SEQ ID NO:112.

[0283] On the other hand, the second antigen is CEA, particularly human CEA, and the second antigen-binding domain (and the third antigen-binding domain, if present) comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:113, HCDR 2 of SEQ ID NO:114, and HCDR 3 of SEQ ID NO:115; the light chain variable region comprises the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:117, LCDR 2 of SEQ ID NO:118, and LCDR 3 of SEQ ID NO:119.

[0284] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is derived from a humanized antibody. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a humanized antigen-binding domain (i.e., the antigen-binding domain of the humanized antibody). In yet another aspect, the VH and / or VL of the second antigen-binding domain (and, if present, the third antigen-binding domain) are humanized variable regions.

[0285] In one aspect, the VH and / or VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) contain a receptor human frame, such as the human immunoglobulin frame or the human common frame.

[0286] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO:116. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:116. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:116. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:116. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identical contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CEA. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:116 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, VH comprises the amino acid sequence of SEQ ID NO:116. Optionally, VH comprises the amino acid sequence of SEQ ID NO:116, including post-translational modifications of that sequence.

[0287] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:120. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:120. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:120. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:120. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identical contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CEA. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:120 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:120. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:120, including post-translational modifications of that sequence.

[0288] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO: 116, and the VL of the second antigen-binding domain comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO: 120. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO: 116, and the VL comprises the amino acid sequence of SEQ ID NO: 120.

[0289] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:116; and the VL comprises the amino acid sequence of SEQ ID NO:120.

[0290] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the VH sequence of SEQ ID NO:116 and the VL sequence of SEQ ID NO:120.

[0291] On the other hand, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:116; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:120.

[0292] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the HCDR1, HCDR2 and HCDR3 amino acid sequences of VH in SEQ ID NO:116 and the LCDR1, LCDR2 and LCDR3 amino acid sequences of VL in SEQ ID NO:120.

[0293] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the heavy chain CDR sequence of the VH of SEQ ID NO:116, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VH of SEQ ID NO:116. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:116, and a frame having at least 95% sequence identity with the frame sequence of the VH of SEQ ID NO:116. In yet another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:116, and a frame having at least 98% sequence identity with the frame sequence of the VH of SEQ ID NO:116.

[0294] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the light chain CDR sequence of the VL of SEQ ID NO:120, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VL of SEQ ID NO:120. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:120, and a frame having at least 95% sequence identity with the frame sequence of the VL of SEQ ID NO:120. In yet another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:120, and a frame having at least 98% sequence identity with the frame sequence of the VL of SEQ ID NO:120.

[0295] In some respects, the second antigen is GPRC5D, especially human GPRC5D.

[0296] In one aspect, the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:61, the HCDR 2 of SEQ ID NO:62, and the HCDR 3 of SEQ ID NO:63; the light chain variable region comprising the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:65, the LCDR 2 of SEQ ID NO:66, and the LCDR 3 of SEQ ID NO:67.

[0297] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is derived from a humanized antibody. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a humanized antigen-binding domain (i.e., the antigen-binding domain of the humanized antibody). In yet another aspect, the VH and / or VL of the second antigen-binding domain (and, if present, the third antigen-binding domain) are humanized variable regions.

[0298] In one aspect, the VH and / or VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) contain a receptor human frame, such as the human immunoglobulin frame or the human common frame.

[0299] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO:64. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:64. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:64. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:64. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to GPRC5D. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:64 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, VH comprises the amino acid sequence of SEQ ID NO:64. Optionally, VH comprises the amino acid sequence of SEQ ID NO:64, including post-translational modifications of that sequence.

[0300] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:68. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:68. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:68. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:68. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to GPRC5D. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:68 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:68. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:68, including post-translational modifications of that sequence.

[0301] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:64, and the VL of the second antigen-binding domain comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:68. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO:64, and the VL comprises the amino acid sequence of SEQ ID NO:68.

[0302] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:64; and the VL comprises the amino acid sequence of SEQ ID NO:68.

[0303] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the VH sequence of SEQ ID NO:64 and the VL sequence of SEQ ID NO:68.

[0304] On the other hand, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:64; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:68.

[0305] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the HCDR1, HCDR2 and HCDR3 amino acid sequences of VH in SEQ ID NO:64 and the LCDR1, LCDR2 and LCDR3 amino acid sequences of VL in SEQ ID NO:68.

[0306] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the heavy chain CDR sequence of the VH of SEQ ID NO:64, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VH of SEQ ID NO:64. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:64, and a frame having at least 95% sequence identity with the frame sequence of the VH of SEQ ID NO:64. In yet another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:64, and a frame having at least 98% sequence identity with the frame sequence of the VH of SEQ ID NO:64.

[0307] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the light chain CDR sequence of the VL of SEQ ID NO:68, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VL of SEQ ID NO:68. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:68, and a frame having at least 95% sequence identity with the frame sequence of the VL of SEQ ID NO:68. In yet another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:68, and a frame having at least 98% sequence identity with the frame sequence of the VL of SEQ ID NO:68.

[0308] In some respects, the second antigen is CD19, especially human CD19.

[0309] In one aspect, the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:75, the HCDR 2 of SEQ ID NO:76, and the HCDR 3 of SEQ ID NO:77; the light chain variable region comprising the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:79, the LCDR 2 of SEQ ID NO:80, and the LCDR 3 of SEQ ID NO:81.

[0310] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is derived from a humanized antibody. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a humanized antigen-binding domain (i.e., the antigen-binding domain of the humanized antibody). In yet another aspect, the VH and / or VL of the second antigen-binding domain (and, if present, the third antigen-binding domain) are humanized variable regions.

[0311] In one aspect, the VH and / or VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) contain a receptor human frame, such as the human immunoglobulin frame or the human common frame.

[0312] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO:78. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:78. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:78. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:78. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CD19. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:78 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, VH comprises the amino acid sequence of SEQ ID NO:78. Optionally, VH comprises the amino acid sequence of SEQ ID NO:78, including post-translational modifications of that sequence.

[0313] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:82. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:82. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:82. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:82. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CD19. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:82 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:82. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:82, including post-translational modifications of that sequence.

[0314] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:78, and the VL of the second antigen-binding domain comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:82. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO:78, and the VL comprises the amino acid sequence of SEQ ID NO:82.

[0315] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:78; and the VL comprises the amino acid sequence of SEQ ID NO:82.

[0316] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the VH sequence of SEQ ID NO:78 and the VL sequence of SEQ ID NO:82.

[0317] On the other hand, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:78; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:82.

[0318] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the HCDR1, HCDR2 and HCDR3 amino acid sequences of VH in SEQ ID NO:78 and the LCDR1, LCDR2 and LCDR3 amino acid sequences of VL in SEQ ID NO:82.

[0319] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the heavy chain CDR sequence of the VH of SEQ ID NO:78, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VH of SEQ ID NO:78. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:78, and a frame having at least 95% sequence identity with the frame sequence of the VH of SEQ ID NO:78. In yet another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:78, and a frame having at least 98% sequence identity with the frame sequence of the VH of SEQ ID NO:78.

[0320] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the light chain CDR sequence of the VL of SEQ ID NO:82, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VL of SEQ ID NO:82. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:82, and a frame having at least 95% sequence identity with the frame sequence of the VL of SEQ ID NO:82. In yet another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:82, and a frame having at least 98% sequence identity with the frame sequence of the VL of SEQ ID NO:82.

[0321] On the other hand, the second antigen is CD19, particularly human CD19, and the second antigen-binding domain (and the third antigen-binding domain, if present) comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:83, HCDR 2 of SEQ ID NO:84, and HCDR 3 of SEQ ID NO:85; the light chain variable region comprises the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:87, LCDR 2 of SEQ ID NO:88, and LCDR 3 of SEQ ID NO:89.

[0322] In one aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is derived from a humanized antibody. In another aspect, the second antigen-binding domain (and, if present, the third antigen-binding domain) is a humanized antigen-binding domain (i.e., the antigen-binding domain of the humanized antibody). In yet another aspect, the VH and / or VL of the second antigen-binding domain (and, if present, the third antigen-binding domain) are humanized variable regions.

[0323] In one aspect, the VH and / or VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) contain a receptor human frame, such as the human immunoglobulin frame or the human common frame.

[0324] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more heavy chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the heavy chain variable region sequence of SEQ ID NO:86. In one aspect, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:86. In one aspect, the VH comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:86. In one aspect, the VH comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:86. In some aspects, the VH sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CD19. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:86 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, VH comprises the amino acid sequence of SEQ ID NO:86. Optionally, VH comprises the amino acid sequence of SEQ ID NO:86, including post-translational modifications of that sequence.

[0325] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises one or more light chain framework sequences (i.e., FR1, FR2, FR3, and / or FR4 sequences) of the light chain variable region sequence of SEQ ID NO:90. In one aspect, the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:90. In one aspect, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO:90. In one aspect, the VL comprises an amino acid sequence that is at least about 98% identical to the amino acid sequence of SEQ ID NO:90. In some aspects, the VL sequence having at least 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conserved substitutions), insertions, or deletions relative to the reference sequence, but the antibody containing this sequence retains its ability to bind to CD19. In some aspects, a total of 1 to 10 amino acids in the amino acid sequence of SEQ ID NO:90 have been substituted, inserted, and / or deleted. In some respects, substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In one respect, the VL comprises the amino acid sequence of SEQ ID NO:90. Optionally, the VL comprises the amino acid sequence of SEQ ID NO:90, including post-translational modifications of that sequence.

[0326] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:86, and the VL of the second antigen-binding domain comprises at least about 95%, 96%, 97%, 98%, or 99% of the amino acid sequence identical to that of SEQ ID NO:90. In another aspect, the VH comprises the amino acid sequence of SEQ ID NO:86, and the VL comprises the amino acid sequence of SEQ ID NO:90.

[0327] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the amino acid sequence of SEQ ID NO:86; and the VL comprises the amino acid sequence of SEQ ID NO:90.

[0328] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the VH sequence of SEQ ID NO:86 and the VL sequence of SEQ ID NO:90.

[0329] On the other hand, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises VH and VL, wherein the VH comprises the heavy chain CDR sequence of VH of SEQ ID NO:86; and the VL comprises the light chain CDR sequence of VL of SEQ ID NO:90.

[0330] In another aspect, the second antigen-binding domain (and the third antigen-binding domain, if present) comprises the HCDR1, HCDR2 and HCDR3 amino acid sequences of VH in SEQ ID NO:86 and the LCDR1, LCDR2 and LCDR3 amino acid sequences of VL in SEQ ID NO:90.

[0331] In one aspect, the VH of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the heavy chain CDR sequence of the VH of SEQ ID NO:86, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VH of SEQ ID NO:86. In another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:86, and a frame having at least 95% sequence identity with the frame sequence of the VH of SEQ ID NO:86. In yet another aspect, the VH comprises the heavy chain CDR sequence of the VH of SEQ ID NO:86, and a frame having at least 98% sequence identity with the frame sequence of the VH of SEQ ID NO:86.

[0332] In one aspect, the VL of the second antigen-binding domain (and, where present, the third antigen-binding domain) comprises the light chain CDR sequence of the VL of SEQ ID NO:90, and a frame having at least 95%, 96%, 97%, 98%, or 99% sequence identity with the frame sequence of the VL of SEQ ID NO:90. In another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:90, and a frame having at least 95% sequence identity with the frame sequence of the VL of SEQ ID NO:90. In yet another aspect, the VL comprises the light chain CDR sequence of the VL of SEQ ID NO:90, and a frame having at least 98% sequence identity with the frame sequence of the VL of SEQ ID NO:90.

[0333] c) Charged modification

[0334] The (multispecific) antibody of the present invention may contain amino acid substitutions in the Fab molecule therein, which are particularly effective in reducing mismatches between the light chain and the mismatched heavy chain (Bence-Jones-type byproducts). These mismatches can occur in the generation of Fab-based multispecific antibodies, wherein the bispecific / multispecific antigen-binding molecule has VH / VL exchanges in one of its binding arms (or multiple arms in the case of a molecule containing more than two antigen-binding Fab molecules) (see also PCT Publication WO 2015 / 150447, in particular examples therein, the entire contents of which are incorporated herein by reference). The ratio of desired (multispecific) antibody to undesirable byproducts, particularly Bence-Jones-type byproducts appearing in multispecific antibodies with VH / VL domain exchanges in one of the binding arms of the (multispecific) antibody, can be improved by introducing charged amino acids with opposite charges at specific amino acid positions in the CH1 and CL domains (sometimes referred to herein as "charge modification").

[0335] Therefore, in some respects, the first and second antigen-binding domains (and, where present, the third antigen-binding domain) of the (multispecific) antibody are aspects of the Fab molecule, and in one of these antigen-binding domains (particularly the first antigen-binding domain), the variable domains VL and VH of the Fab light chain and Fab heavy chain are interchanged.

[0336] i) In the constant domain CL of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 124 is replaced by a positively charged amino acid (according to Kabat numbering), and wherein in the constant domain CH1 of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 147 or the amino acid at position 213 is replaced by a negatively charged amino acid (according to Kabat EU indexing); or

[0337] ii) In the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is replaced by a positively charged amino acid (according to Kabat number), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 or position 213 is replaced by a negatively charged amino acid (according to Kabat EU index number).

[0338] The (multispecific) antibody does not contain the two modifications mentioned in i) and ii). The constant domains CL and CH1 of the antigen-binding domain with VH / VL exchange do not substitute for each other (i.e., remain unexchanged).

[0339] In a more specific sense,

[0340] i) In the constant domain CL of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 124 is independently substituted by lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 147 or the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (according to Kabat EU index number); or

[0341] ii) In the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 or the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0342] In one aspect, in the constant domain CL of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 147 or at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0343] On the other hand, in the constant domain CL of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the second antigen-binding domain (and, where present, the third antigen-binding domain), the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0344] In a preferred aspect, in the constant domain CL of the second antigen-binding domain (and, if present, the third antigen-binding domain), the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering) and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the second antigen-binding domain (and, if present, the third antigen-binding domain), the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering) and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0345] In a more preferred aspect, in the constant domain CL of the second antigen-binding domain (and the third antigen-binding domain when present), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by lysine (K) (according to Kabat number), and in the constant domain CH1 of the second antigen-binding domain (and the third antigen-binding domain when present), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number).

[0346] In an even more preferred aspect, in the constant domain CL of the second antigen-binding domain (and the third antigen-binding domain when present), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by arginine (R) (according to Kabat number), and in the constant domain CH1 of the second antigen-binding domain (and the third antigen-binding domain when present), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number).

[0347] In a preferred aspect, if the amino acid substitution according to the above aspects is carried out in the constant domains CL and CH1 of the second antigen-binding domain (and the third antigen-binding domain when present), then the constant domain CL of the second antigen-binding domain (and the third antigen-binding domain when present) is a κ isotype.

[0348] Alternatively, the amino acid substitutions according to the above aspects can be carried out in the constant domains CL and CH1 of the first antigen-binding domain, rather than in the constant domains CL and CH1 of the second antigen-binding domain (and, where present, the third antigen-binding domain). In a preferred embodiment of this aspect, the constant domain CL of the first antigen-binding domain is of the κ isotype.

[0349] Therefore, in one aspect, in the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 or the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0350] In another aspect, in the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is independently replaced by lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 is independently replaced by glutamic acid (E) or aspartic acid (D) (according to Kabat EU index numbering).

[0351] In another aspect, in the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering) and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing) and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing).

[0352] In one aspect, in the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is replaced by lysine (K) (according to Kabat numbering) and the amino acid at position 123 is replaced by lysine (K) (according to Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index numbering) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index numbering).

[0353] On the other hand, in the constant domain CL of the first antigen-binding domain, the amino acid at position 124 is replaced by lysine (K) (according to Kabat numbering) and the amino acid at position 123 is replaced by arginine (R) (according to Kabat numbering), and in the constant domain CH1 of the first antigen-binding domain, the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index numbering) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index numbering).

[0354] In a preferred aspect, the (multispecific) antibody of the present invention comprises (A) a first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and comprises (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH comprising the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; and (d) a VH comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:10. HCDR 3 of SEQ ID NO:11 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7 and HCDR 3 of SEQ ID NO:13; and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21 and LCDR of SEQ ID NO:22. 3, and (B) a second antigen-binding domain and optionally a third antigen-binding domain that bind to the second antigen; wherein in the constant domain CL of the second (and, if present, the third) antigen-binding domain, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering) (in a preferred aspect, substituted with lysine (K) or arginine (R) independently) and the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (according to Kabat numbering) (in a preferred aspect, substituted with lysine (K) or arginine (R) independently); and in the constant domain CH1 of the second (and, if present, the third) antigen-binding domain, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing) and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (according to Kabat EU indexing).

[0355] d) Multispecific antibody forms

[0356] The (multispecific) antibody according to the present invention can have multiple configurations. An exemplary configuration is shown in... Figure 1 As described in the text.

[0357] In a preferred embodiment, the antigen-binding domain contained in the (multispecific) antibody is a Fab molecule. In this regard, the first, second, and third antigen-binding domains, etc., may be referred to herein as the first, second, and third Fab molecules, respectively.

[0358] In one aspect, the first antigen-binding domain and the second antigen-binding domain of the (multispecific) antibody are fused together, optionally via a peptide linker. In a preferred aspect, each of the first and second antigen-binding domains is a Fab molecule. In one such aspect, the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain. In another such aspect, the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain. Wherein (i) the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain, or (ii) the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, the Fab light chain of the first antigen-binding domain and the Fab light chain of the second antigen-binding domain may optionally be fused together via a peptide linker.

[0359] It has the ability to interact with a second antigen (e.g., target cell antigen, such as TYRP-1, CEA, GPRC5D, or CD19, e.g., ... Figure 1 A, Figure 1 D、 Figure 1 G, Figure 1 H, Figure 1 K, Figure 1 Multispecific antibodies (such as Fab molecules) that specifically bind to a single antigen-binding domain (as shown in L) are useful, especially when the internalization of a second antigen is expected after binding to a high-affinity antigen-binding domain. In this case, the presence of more than one antigen-binding domain specific to the second antigen may enhance the internalization of the second antigen, thereby reducing its usability.

[0360] However, in other cases, it may contain two or more pairs of secondary antigens, such as target cell antigens (see [link to relevant documentation]). Figure 1 B Figure 1 C Figure 1 E, Figure 1 F, Figure 1 I, Figure 1 J、 Figure 1 M or Figure 1(As shown in N) Antibodies with specific antigen-binding domains (multispecific) (such as Fab molecules) would be advantageous, for example, to optimize targeting of target sites or to allow cross-linking of target cell antigens.

[0361] Therefore, in a preferred aspect, the (multispecific) antibody according to the invention comprises a third antigen-binding domain.

[0362] On one hand, the third antigen-binding domain binds to the second antigen (e.g., target cell antigens such as TYRP-1, CEA, GPRC5D, or CD19). On the other hand, the third antigen-binding domain is a Fab molecule.

[0363] In one respect, the third antigenic domain is identical to the second antigen-binding domain.

[0364] In some respects, the third and second antigen-binding domains are each Fab molecules, and the third antigen-binding domain is identical to the second antigen-binding domain. Therefore, in these respects, the second and third antigen-binding domains contain the same heavy and light chain amino acid sequences and have the same domain arrangement (i.e., conventional or crossed). Furthermore, in these respects, the third antigen-binding domain contains the same amino acid substitutions (if any) as the second antigen-binding domain. For example, amino acid substitutions described herein as “charge-modified” will be made in the constant domains CL and CH1 of the second and third antigen-binding domains, respectively. Alternatively, the amino acid substitutions may be made in the constant domains CL and CH1 of the first antigen-binding domain (which, in a preferred respect, is also a Fab molecule), but not in the constant domains CL and CH1 of the second and third antigen-binding domains.

[0365] Similar to the second antigen-binding domain, the third antigen-binding domain is preferably a conventional Fab molecule. However, the aspect in which the second and third antigen-binding domains are cross-Fab molecules (and the first antigen-binding domain is a conventional Fab molecule) is also considered. Therefore, in a preferred aspect, the second and third antigen-binding domains are each conventional Fab molecules, and the first antigen-binding domain is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL or the constant domains CL and CH1 of the Fab heavy and light chains are exchanged / substituted for each other. In other aspects, the second and third antigen-binding domains are each cross-Fab molecules and the first antigen-binding domain is a conventional Fab molecule.

[0366] If a third antigen-binding domain is present, in a preferred embodiment, the first antigen-binding domain binds to CD3, and the second antigen-binding domain binds to a second antigen, particularly a target cell antigen (such as TYRP-1, CEA, GPRC5D, or CD19).

[0367] In a preferred aspect, the (multispecific) antibody of the present invention comprises an Fc domain consisting of a first subunit and a second subunit. The first and second subunits of the Fc domain are capable of stable association.

[0368] The (multispecific) antibody according to the invention can have different conformations, i.e., the first antigen-binding domain, the second antigen-binding domain (and optionally the third antigen-binding domain) can be fused to each other and to the Fc domain in different ways. Components can be fused directly to each other, or preferably fused via one or more suitable peptide linkers. When the Fab molecule fuses to the N-terminus of a subunit of the Fc domain, the fusion is typically via an immunoglobulin hinge region.

[0369] In some aspects, the first antigen-binding domain and the second antigen-binding domain are each Fab molecules, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In such aspects, the second antigen-binding domain may be fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain or to the N-terminus of another subunit of the Fc domain. In preferred aspects of this type, the second antigen-binding domain is a conventional Fab molecule, and the first antigen-binding domain is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL or the constant domains CL and CH1 of the Fab heavy and light chains are exchanged / substituted for each other. In other aspects of this type, the second antigen-binding domain is a cross-Fab molecule, and the first antigen-binding domain is a conventional Fab molecule.

[0370] In one aspect, the first antigen-binding domain and the second antigen-binding domain are each Fab molecules, with the first antigen-binding domain fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain, and the second antigen-binding domain fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain. In a more specific aspect, the (multispecific) antibody essentially consists of first and second Fab molecules, an Fc domain formed by first and second subunits, and optionally one or more peptide linkers, wherein the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule, and the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. This configuration is... Figure 1 G and Figure 1 K is schematically depicted (in these examples, the first antigen-binding domain is a VH / VL cross-Fab molecule). Optionally, the Fab light chain of the first Fab molecule and the Fab light chain of the second Fab molecule may be further fused to each other.

[0371] On the other hand, the first antigen-binding domain and the second antigen-binding domain are each Fab molecules, and each of the first and second antigen-binding domains is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain. Specifically, the (multispecific) antibody essentially consists of a first Fab molecule and a second Fab molecule, an Fc domain composed of the first and second subunits, and optionally one or more peptide linkers, wherein the first Fab molecule and the second Fab molecule are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain. This configuration... Figure 1 A and Figure 1 Figure D schematically depicts (in these examples, the first antigen-binding domain is a VH / VL cross-linked Fab molecule and the second antigen-binding domain is a conventional Fab molecule). The first and second Fab molecules can be fused to the Fc domain directly or via peptide linkers. In a preferred embodiment, the first and second Fab molecules are each fused to the Fc domain via an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is the human IgG1 hinge region, particularly when the Fc domain is an IgG1 Fc domain.

[0372] In some aspects, the first antigen-binding domain and the second antigen-binding domain are each Fab molecules, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In such aspects, the first antigen-binding domain may be fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain or (as described above) to the N-terminus of another subunit of the Fc domain. In a preferred aspect of this type, the second antigen-binding domain is a conventional Fab molecule, and the first antigen-binding domain is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL or the constant domains CL and CH1 of the Fab heavy and light chains are exchanged / substituted for each other. In other aspects of this type, the second antigen-binding domain is a cross-Fab molecule, and the first antigen-binding domain is a conventional Fab molecule.

[0373] In one aspect, the first antigen-binding domain and the second antigen-binding domain are each Fab molecules, the second antigen-binding domain being fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain, and the first antigen-binding domain being fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain. In a more specific aspect, the (multispecific) antibody essentially consists of first and second Fab molecules, an Fc domain formed by first and second subunits, and optionally one or more peptide linkers, wherein the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. This configuration is... Figure 1 H and Figure 1 The diagram in L is schematically depicted (in these examples, the first antigen-binding domain is a VH / VL cross-Fab molecule and the second antigen-binding domain is a conventional Fab molecule). Optionally, the Fab light chains of the first Fab molecule and the Fab light chains of the second Fab molecule may be further fused together.

[0374] In some aspects, the third antigen-binding domain, particularly the third Fab molecule, is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or second subunit of the Fc domain. In preferred aspects of this type, the second and third antigen-binding domains are each conventional Fab molecules, and the first antigen-binding domain is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL or the constant domains CL and CH1 of the Fab heavy and light chains are exchanged / substituted for each other. In other aspects of this type, the second and third antigen-binding domains are each cross-Fab molecules, and the first antigen-binding domain is a conventional Fab molecule.

[0375] In a preferred embodiment, the first and third antigen-binding domains are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule. Specifically, the (multispecific) antibody essentially comprises first, second, and third Fab molecules, an Fc domain formed by the first and second subunits, and optionally one or more peptide linkers, wherein the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule, and the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the first subunit of the Fc domain, and wherein the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain. This configuration... Figure 1 B and Figure 1E schematically depicts (in these examples, the first antigen-binding domain is a VH / VL cross-Fab molecule, and the second and third antigen-binding domains are conventional Fab molecules), and Figure 1 J and Figure 1 N (In these examples, the first antigen-binding domain is a conventional Fab molecule, and the second and third antigen-binding domains are VH / VL cross-linked Fab molecules). The first and third Fab molecules can be fused to the Fc domain directly or via peptide linkers. In a preferred embodiment, the first and third Fab molecules are each fused to the Fc domain via an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is the human IgG1 hinge region, particularly when the Fc domain is the IgG1 Fc domain. Optionally, the Fab light chains of the first and second Fab molecules can be additionally fused to each other.

[0376] In another aspect of this type, the second and third antigen-binding domains are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain. In a specific aspect, the (multispecific) antibody essentially consists of first, second, and third Fab molecules, an Fc domain formed by the first and second subunits, and optionally one or more peptide linkers, wherein the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the first subunit of the Fc domain, and wherein the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain. This configuration is... Figure 1 C and Figure 1 F schematically depicts (in these examples, the first antigen-binding domain is a VH / VL cross-Fab molecule, and the second and third antigen-binding domains are conventional Fab molecules), and Figure 1 I and Figure 1 M (In these examples, the first antigen-binding domain is a conventional Fab molecule, and the second and third antigen-binding domains are VH / VL cross-linked Fab molecules). The second and third Fab molecules can be fused to the Fc domain directly or via peptide linkers. In a preferred embodiment, the second and third Fab molecules are each fused to the Fc domain via an immunoglobulin hinge region. In a specific embodiment, the immunoglobulin hinge region is the human IgG1 hinge region, particularly when the Fc domain is the IgG1 Fc domain. Optionally, the Fab light chains of the first and second Fab molecules can be additionally fused to each other.

[0377] In the configuration of a (multispecific) antibody, a Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of each subunit of the Fc domain via an immunoglobulin hinge region, the two Fab molecules, the hinge region, and the Fc domain essentially forming an immunoglobulin molecule. In a preferred aspect, the immunoglobulin molecule is an IgG class immunoglobulin. In an even more preferred aspect, the immunoglobulin is an IgG1 subclass immunoglobulin. In another aspect, the immunoglobulin is an IgG4 subclass immunoglobulin. In yet another preferred aspect, the immunoglobulin is a human immunoglobulin. In other aspects, the immunoglobulin is a chimeric immunoglobulin or a humanized immunoglobulin. In one aspect, the immunoglobulin includes a human constant region, particularly a human Fc region.

[0378] In some of the (multispecific) antibodies of the present invention, the Fab light chains of a first Fab molecule and a second Fab molecule are fused together, optionally via peptide linkers. Depending on the configuration of the first and second Fab molecules, the Fab light chain of the first Fab molecule may be fused at its C-terminus to the N-terminus of the Fab light chain of the second Fab molecule, or the Fab light chain of the second Fab molecule may be fused at its C-terminus to the N-terminus of the Fab light chain of the first Fab molecule. The fusion of the Fab light chains of the first and second Fab molecules further reduces mismatches between unmatched Fab heavy and light chains, and also reduces the number of plasmids required to express some of the (multispecific) antibodies of the present invention.

[0379] The antigen-binding domain can be fused to the Fc domain directly or via a peptide linker containing one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art and described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S). n (SG4) n (G4S) n G4 (SG4) n Or (G4S) n G5 peptide linker. "n" is typically an integer from 1 to 10, and usually from 2 to 4. In one aspect, the peptide linker is at least 5 amino acids long; in another aspect, it is 5 to 100 amino acids long; and in yet another aspect, it is 10 to 50 amino acids long. In one aspect, the peptide linker is (GxS). n Or (GxS) n G mThe peptide linker is defined as follows: G = glycine, S = serine, and (x = 3, n = 3, 4, 5, or 6, and m = 0, 1, 2, or 3) or (x = 4, n = 1, 2, 3, 4, or 5, and m = 0, 1, 2, 3, 4, or 5); in one aspect, x = 4 and n = 2 or 3; in another aspect, x = 4 and n = 2; in yet another aspect, x = 4, n = 1, and m = 5. In one aspect, the peptide linker is (G4S)2. In another aspect, the peptide linker is G4SG5. A particularly suitable peptide linker for fusing the Fab light chains of the first Fab molecule and the second Fab molecule to each other is (G4S)2. An exemplary peptide linker suitable for linking the Fab heavy chains of the first Fab fragment and the second Fab fragment comprises the sequence (D)-(G4S)2 (SEQ ID NO 48 and 49). Another suitable such linker comprises the sequence (D)-G4SG5 (SEQ ID NO 103 and SEQ ID NO 104). Additionally, the linker may include a portion of an immunoglobulin hinge region. In particular, in the case of fusion of the Fab molecule with the N-terminus of an Fc domain subunit, fusion may occur via the immunoglobulin hinge region or a portion thereof, with or without an additional peptide linker.

[0380] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab light chain variable region of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by the light chain variable region), the Fab heavy chain constant region subsequently sharing a carboxyl-terminal peptide bond (VL) with the Fc domain subunit. (1) -CH1 (1) -CH2-CH3(-CH4)), and polypeptides in which the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond (VH) with the Fc domain subunit. (2) -CH1 (2) -CH2-CH3(-CH4)). In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab heavy chain of the first Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the first Fab molecule. (1) -CL (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In some respects, peptides are covalently linked, for example, by disulfide bonds.

[0381] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the variable region of the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), the Fab heavy chain constant region subsequently sharing a carboxyl-terminal peptide bond (VH) with the Fc domain subunit. (1) -CL (1) -CH2-CH3(-CH4)), and polypeptides in which the Fab heavy chain of the second Fab molecule shares a carboxyl-terminal peptide bond (VH) with the Fc domain subunit. (2) -CH1 (2) -CH2-CH3(-CH4)). In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab light chain of the first Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the first Fab molecule. (1) -CH1 (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In some respects, peptides are covalently linked, for example, by disulfide bonds.

[0382] In some respects, (multispecific) antibodies comprise peptides in which the variable region of the Fab light chain of a first Fab molecule shares a C-terminal peptide bond with the constant region of the Fab heavy chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the variable region of the heavy chain is replaced by the variable region of the light chain), the constant region of the Fab heavy chain then shares a C-terminal peptide bond with the Fab heavy chain of a second Fab molecule, the Fab heavy chain of the second Fab molecule then sharing a C-terminal peptide bond with an Fc domain subunit (VL). (1) -CH1 (1) -VH (2) -CH1 (2) -CH2-CH3(-CH4)). In other respects, (multispecific) antibodies comprise polypeptides in which the Fab heavy chain of a second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab light chain of a first Fab molecule, the variable region of the Fab light chain of the first Fab molecule subsequently sharing a C-terminal peptide bond with the constant region of the Fab heavy chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by the light chain variable region), the constant region of the Fab heavy chain subsequently sharing a C-terminal peptide bond (VH) with the Fc domain subunit. (2) -CH1 (2) -VL (1) -CH1 (1)-CH2-CH3(-CH4)). In some of these aspects, the (multispecific) antibody further comprises a cross-linked Fab light chain polypeptide of the first Fab molecule, wherein the variable region of the Fab heavy chain of the first Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the first Fab molecule. (1) -CL (1) And it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In other such aspects, the (multispecific) antibody further comprises a polypeptide in which the variable region of the Fab heavy chain of the first Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule, and the constant region of the Fab light chain of the first Fab molecule subsequently shares a carboxyl-terminal peptide bond (VH) with the polypeptide of the Fab light chain of the second Fab molecule. (1) -CL (1) -VL (2) -CL (2) ), or wherein the Fab light chain polypeptide of the second Fab molecule shares a carboxyl-terminal peptide bond with the variable region of the Fab heavy chain of the first Fab molecule, and the variable region of the Fab heavy chain of the first Fab molecule subsequently shares a carboxyl-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (VL (2) -CL (2) -VH (1) -CL (1) Depending on the circumstances, (multispecific) antibodies based on these aspects may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide in which the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH). (3) -CH1 (3) -CH2-CH3(-CH4)), and the Fab light chain polypeptide (VL) of the third Fab molecule. (3) -CL (3) In some respects, peptides are covalently linked, for example, by disulfide bonds.

[0383] In some respects, (multispecific) antibodies comprise peptides in which the variable region of the Fab heavy chain of a first Fab molecule shares a C-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), the Fab heavy chain constant region then shares a C-terminal peptide bond with the Fab heavy chain of a second Fab molecule, the Fab heavy chain of the second Fab molecule then shares a C-terminal peptide bond with the Fc domain subunit (VH). (1) -CL (1) -VH (2) -CH1(2) -CH2-CH3(-CH4)). In other respects, (multispecific) antibodies comprise polypeptides in which the Fab heavy chain of a second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab heavy chain of a first Fab molecule, and the variable region of the Fab light chain of the first Fab molecule subsequently shares a C-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), and the Fab heavy chain constant region subsequently shares a C-terminal peptide bond (VH) with the Fc domain subunit. (2) -CH1 (2) -VH (1) -CL (1) -CH2-CH3(-CH4)). In some of these aspects, the (multispecific) antibody further comprises a cross-linked Fab light chain polypeptide of the first Fab molecule, wherein the variable region of the Fab light chain of the first Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the first Fab molecule. (1) -CH1 (1) And it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In other such aspects, the (multispecific) antibody further comprises a polypeptide in which the variable region of the Fab light chain of the first Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab heavy chain of the first Fab molecule, which in turn shares a carboxyl-terminal peptide bond with the Fab light chain polypeptide of the second Fab molecule (VL). (1) -CH1 (1) -VL (2) -CL (2) ), or wherein the Fab light chain polypeptide of the second Fab molecule shares a carboxyl-terminal peptide bond with the variable region of the Fab heavy chain of the first Fab molecule, and the variable region of the Fab heavy chain of the first Fab molecule subsequently shares a carboxyl-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (VL (2) -CL (2) -VH (1) -CL (1) Depending on the circumstances, (multispecific) antibodies based on these aspects may further comprise (i) an Fc domain subunit polypeptide (CH2-CH3(-CH4)), or (ii) a polypeptide in which the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond with the Fc domain subunit (VH). (3) -CH1 (3) -CH2-CH3(-CH4)), and the Fab light chain polypeptide (VL) of the third Fab molecule. (3) -CL (3)In some respects, peptides are covalently linked, for example, by disulfide bonds.

[0384] In some respects, (multispecific) antibodies do not contain an Fc domain. In a preferred such respect, the second antigen-binding domain and (if present) the third antigen-binding domain are each conventional Fab molecules, and the first antigen-binding domain is a cross-Fab molecule as described herein, i.e., a Fab molecule in which the variable domains VH and VL or the constant domains CL and CH1 of the Fab heavy and light chains are exchanged / substituted for each other. In other such respects, the second antigen-binding domain and (if present) the third antigen-binding domain are each cross-Fab molecules, and the first antigen-binding domain is a conventional Fab molecule.

[0385] In one such aspect, a (multispecific) antibody essentially consists of a first antigen-binding domain, a second antigen-binding domain, and optionally one or more peptide linkers, wherein both the first and second antigen-binding domains are Fab molecules, and the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain. This configuration is... Figure 1 O and Figure 1 S is schematically depicted (in these examples, the first antigen-binding domain is a VH / VL cross-Fab molecule and the second antigen-binding domain is a conventional Fab molecule).

[0386] In another aspect of this kind, (multispecific) antibodies essentially consist of a first antigen-binding domain and a second antigen-binding domain, and optionally one or more peptide linkers, wherein both the first and second antigen-binding domains are Fab molecules, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen-binding domain. This configuration is... Figure 1 P and Figure 1 The diagram in T is schematically depicted (in these examples, the first antigen-binding domain is a VH / VL cross-Fab molecule and the second antigen-binding domain is a conventional Fab molecule).

[0387] In some aspects, the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule, and the (multispecific) antibody further comprises a third antigen-binding domain, particularly a third Fab molecule, wherein the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule. In some such aspects, the (multispecific) antibody essentially consists of first, second, and third Fab molecules and optionally one or more peptide linkers, wherein the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first Fab molecule, and the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule. This configuration is... Figure 1 Q and Figure 1 The diagram in U is schematically depicted (in these examples, the first antigen-binding domain is a VH / VL cross-Fab molecule, and the second and third antigen-binding domains are each conventional Fab molecules), or Figure 1 X and Figure 1 Z (In these examples, the first antigen-binding domain is a conventional Fab molecule, and the second and third antigen-binding domains are each VH / VL cross-Fab molecules).

[0388] In some aspects, the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the (multispecific) antibody further comprises a third antigen-binding domain, particularly a third Fab molecule, wherein the third Fab molecule is fused at the N-terminus of the Fab heavy chain to the C-terminus of the Fab heavy chain of the second Fab molecule. In some such aspects, the (multispecific) antibody essentially consists of first, second, and third Fab molecules and optionally one or more peptide linkers, wherein the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the third Fab molecule is fused at the N-terminus of the Fab heavy chain to the C-terminus of the Fab heavy chain of the second Fab molecule. This configuration is... Figure 1 R and Figure 1 V schematically depicts (in these instances, the first antigen-binding domain is a VH / VL cross-Fab molecule, and the second and third antigen-binding domains are each conventional Fab molecules), or Figure 1 W and Figure 1 Y (In these examples, the first antigen-binding domain is a conventional Fab molecule, and the second and third antigen-binding domains are each VH / VL cross-Fab molecules).

[0389] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab heavy chain of a second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab light chain of a first Fab molecule, the variable region of the Fab light chain of the first Fab molecule subsequently sharing a C-terminal peptide bond with the constant region of the Fab heavy chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the variable region of the heavy chain is replaced by the variable region of the light chain) (VH (2) -CH1 (2) -VL (1) -CH1 (1) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the first Fab molecule. (1) -CL (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) ).

[0390] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab light chain variable region of a first Fab molecule shares a carboxyl-terminal peptide bond with the Fab heavy chain constant region of a first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by a light chain variable region), the Fab heavy chain constant region subsequently sharing a carboxyl-terminal peptide bond (VL) with the Fab heavy chain of a second Fab molecule. (1) -CH1 (1) -VH (2) -CH1 (2) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the first Fab molecule. (1) -CL (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) ).

[0391] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab heavy chain of a second Fab molecule shares a C-terminal peptide bond with the variable region of the Fab heavy chain of a first Fab molecule, the variable region of the Fab heavy chain of the first Fab molecule subsequently sharing a C-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region) (VH (2) -CH1 (2)-VH (1) -CL (1) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab light chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the first Fab molecule. (1) -CH1 (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) ).

[0392] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the variable region of the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by a light chain constant region), the Fab light chain constant region then sharing a carboxyl-terminal peptide bond (VH) with the Fab heavy chain of a second Fab molecule. (1) -CL (1) -VH (2) -CH1 (2) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab light chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the first Fab molecule. (1) -CH1 (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) ).

[0393] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab heavy chain of a third Fab molecule shares a C-terminal peptide bond with the Fab heavy chain of a second Fab molecule, the Fab heavy chain of the second Fab molecule subsequently shares a C-terminal peptide bond with the variable region of the Fab light chain of a first Fab molecule, and the variable region of the Fab light chain of the first Fab molecule subsequently shares a C-terminal peptide bond with the constant region of the Fab heavy chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the variable region of the heavy chain is replaced by the variable region of the light chain) (VH (3) -CH1 (3) -VH (2) -CH1 (2) -VL (1) -CH1 (1) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the first Fab molecule.(1) -CL (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In some respects, (multispecific) antibodies further comprise a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0394] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab heavy chain of a third Fab molecule shares a C-terminal peptide bond with the Fab heavy chain of a second Fab molecule, the Fab heavy chain of the second Fab molecule subsequently shares a C-terminal peptide bond with the variable region of the Fab heavy chain of a first Fab molecule, and the variable region of the Fab heavy chain of the first Fab molecule subsequently shares a C-terminal peptide bond with the constant region of the Fab light chain of the first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the constant region of the heavy chain is replaced by the constant region of the light chain) (VH (3) -CH1 (3) -VH (2) -CH1 (2) -VH (1) -CL (1) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab light chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the first Fab molecule. (1) -CH1 (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In some respects, (multispecific) antibodies further comprise a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0395] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab light chain variable region of a first Fab molecule shares a C-terminal peptide bond with the Fab heavy chain constant region of a first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by the light chain variable region), the Fab heavy chain constant region of the first Fab molecule then shares a C-terminal peptide bond with the Fab heavy chain of a second Fab molecule, and the Fab heavy chain of the second Fab molecule then shares a C-terminal peptide bond with the Fab heavy chain of a third Fab molecule (VL). (1) -CH1 (1) -VH (2) -CH1 (2) -VH(3) -CH1 (3) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab heavy chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the first Fab molecule. (1) -CL (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In some respects, (multispecific) antibodies further comprise a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0396] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the variable region of the Fab heavy chain of a first Fab molecule shares a C-terminal peptide bond with the constant region of the Fab light chain of a first Fab molecule (i.e., the first Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), the constant region of the Fab light chain of the first Fab molecule then shares a C-terminal peptide bond with the Fab heavy chain of a second Fab molecule, and the Fab heavy chain of the second Fab molecule then shares a C-terminal peptide bond with the Fab heavy chain of a third Fab molecule (VH). (1) -CL (1) -VH (2) -CH1 (2) -VH (3) -CH1 (3) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab light chain of a first Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the first Fab molecule. (1) -CH1 (1) Furthermore, it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the second Fab molecule. (2) -CL (2) In some respects, (multispecific) antibodies further comprise a Fab light chain polypeptide (VL) of a third Fab molecule. (3) -CL (3) ).

[0397] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab heavy chain of a first Fab molecule shares a C-terminal peptide bond with the variable region of the Fab light chain of a second Fab molecule, the variable region of the Fab light chain of the second Fab molecule subsequently shares a C-terminal peptide bond with the constant region of the Fab heavy chain of the second Fab molecule (i.e., the second Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by the light chain variable region), the constant region of the Fab heavy chain of the second Fab molecule subsequently shares a C-terminal peptide bond with the variable region of the Fab light chain of a third Fab molecule, the variable region of the Fab light chain of the third Fab molecule subsequently shares a C-terminal peptide bond with the constant region of the Fab heavy chain of the third Fab molecule (i.e., the third Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by the light chain variable region) (VH (1) -CH1 (1) -VL (2) -CH1 (2) -VL (3) -CH1 (3) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab heavy chain of a second Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the second Fab molecule. (2) -CL (2) And it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the first Fab molecule. (1) -CL (1) In some respects, (multispecific) antibodies further comprise polypeptides in which the variable region of the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the third Fab molecule. (3) -CL (3) ).

[0398] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab heavy chain of a first Fab molecule shares a C-terminal peptide bond with the variable region of the Fab heavy chain of a second Fab molecule, and the variable region of the Fab heavy chain of the second Fab molecule subsequently shares a C-terminal peptide bond with the constant region of the Fab light chain of the second Fab molecule (i.e., the second Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region), the constant region of the Fab light chain of the second Fab molecule subsequently shares a C-terminal peptide bond with the variable region of the Fab heavy chain of a third Fab molecule, and the variable region of the Fab heavy chain of the third Fab molecule subsequently shares a C-terminal peptide bond with the constant region of the Fab light chain of the third Fab molecule (i.e., the third Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by the light chain constant region) (VH (1) -CH1 (1) -VH(2) -CL (2) -VH (3) -CL (3) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab light chain of a second Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the second Fab molecule. (2) -CH1 (2) And it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the first Fab molecule. (1) -CL (1) In some respects, (multispecific) antibodies further comprise polypeptides in which the variable region of the Fab light chain of the third Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the third Fab molecule. (3) -CH1 (3) ).

[0399] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the Fab light chain variable region of a third Fab molecule shares a C-terminal peptide bond with the Fab heavy chain constant region of a third Fab molecule (i.e., the third Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by a light chain variable region), the Fab heavy chain constant region of the third Fab molecule then shares a C-terminal peptide bond with the Fab light chain variable region of a second Fab molecule, the Fab light chain variable region of the second Fab molecule then shares a C-terminal peptide bond with the Fab heavy chain constant region of the second Fab molecule (i.e., the second Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain variable region is replaced by a light chain variable region), and the Fab heavy chain constant region of the first Fab molecule then shares a C-terminal peptide bond with the Fab heavy chain of the first Fab molecule (VL). (3) -CH1 (3) -VL (2) -CH1 (2) -VH (1) -CH1 (1) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab heavy chain of a second Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the second Fab molecule. (2) -CL (2) And it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the first Fab molecule. (1) -CL (1) In some respects, (multispecific) antibodies further comprise polypeptides in which the variable region of the Fab heavy chain of the third Fab molecule shares a carboxyl-terminal peptide bond (VH) with the constant region of the Fab light chain of the third Fab molecule. (3) -CL(3) ).

[0400] In some aspects, the (multispecific) antibody according to the invention comprises a polypeptide in which the variable region of the Fab heavy chain of a third Fab molecule shares a C-terminal peptide bond with the constant region of the Fab light chain of a third Fab molecule (i.e., the third Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by a light chain constant region), the constant region of the Fab light chain of the third Fab molecule then shares a C-terminal peptide bond with the variable region of the Fab heavy chain of a second Fab molecule, the variable region of the Fab heavy chain of the second Fab molecule then shares a C-terminal peptide bond with the constant region of the Fab light chain of a second Fab molecule (i.e., the second Fab molecule contains a cross-linked Fab heavy chain, wherein the heavy chain constant region is replaced by a light chain constant region), and the constant region of the Fab light chain of the second Fab molecule then shares a C-terminal peptide bond (VH) with the Fab heavy chain of a first Fab molecule. (3) -CL (3) -VH (2) -CL (2) -VH (1) -CH1 (1) In some aspects, (multispecific) antibodies also comprise polypeptides in which the variable region of the Fab light chain of a second Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the second Fab molecule. (2) -CH1 (2) And it shares a carboxyl-terminal peptide bond (VL) with the Fab light chain polypeptide of the first Fab molecule. (1) -CL (1) In some respects, (multispecific) antibodies further comprise polypeptides in which the variable region of the Fab light chain of the third Fab molecule shares a carboxyl-terminal peptide bond (VL) with the constant region of the Fab heavy chain of the third Fab molecule. (3) -CH1 (3) ).

[0401] In one aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0402] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged or the constant domains CL and CH1 are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:10. HCDR 3 of SEQ ID NO:11 or (e) VH, which comprises HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7 and HCDR 3 of SEQ ID NO:13 (especially VH, which comprises HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4 and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), which comprises light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21 and LCDR 3 of SEQ ID NO:22, and

[0403] (B) A second antigen-binding domain that binds to a second antigen, particularly a target cell antigen, especially TYRP-1, CEA, GPRC5D or CD19, wherein the second antigen-binding domain is a (conventional) Fab molecule.

[0404] (C) The Fc domain is composed of a first subunit and a second subunit;

[0405] in

[0406] (i) The first antigen-binding domain of (A) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second antigen-binding domain of (B), and the second antigen-binding domain of (B) is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of (C), or (ii) The second antigen-binding domain of (B) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of (A), and the first antigen-binding domain of (A) is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of (C).

[0407] In a preferred aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising...

[0408] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged or the constant domains CL and CH1 are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:10. (i) HCDR 3 of SEQ ID NO:11 or (e) VH, which includes HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7 and HCDR 3 of SEQ ID NO:13 (especially VH, which includes HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4 and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), which includes light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21 and LCDR 3 of SEQ ID NO:22.

[0409] (B) A second antigen-binding domain and a third antigen-binding domain that bind to a second antigen, particularly a target cell antigen, especially TYRP-1, CEA, GPRC5D, or CD19, wherein each of the second and third antigen-binding domains is a (conventional) Fab molecule; and

[0410] (C) The Fc domain is composed of a first subunit and a second subunit;

[0411] in

[0412] (i) The first antigen-binding domain according to (A) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second antigen-binding domain according to (B), and the second antigen-binding domain according to (B) and the third antigen-binding domain according to (B) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C), or

[0413] (ii) The second antigen-binding domain of (B) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of (A), and the first antigen-binding domain of (A) and the third antigen-binding domain of (B) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of (C).

[0414] In another aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0415] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged or the constant domains CL and CH1 are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:10. HCDR 3 of SEQ ID NO:11 or (e) VH, which comprises HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7 and HCDR 3 of SEQ ID NO:13 (especially VH, which comprises HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4 and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), which comprises light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21 and LCDR 3 of SEQ ID NO:22, and

[0416] (B) A second antigen-binding domain that binds to a second antigen, particularly a target cell antigen, especially TYRP-1, CEA, GPRC5D or CD19, wherein the second antigen-binding domain is a (conventional) Fab molecule.

[0417] (C) The Fc domain is composed of a first subunit and a second subunit;

[0418] in

[0419] (i) The first antigen-binding domain according to (A) and the second antigen-binding domain according to (B) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0420] In all the different configurations of the (multispecific) antibody according to the invention, the amino acid substitutions (“charged modifications”) described herein (if present) may be in the CH1 and CL domains of the second antigen-binding domain and (if present) the third antigen-binding domain / Fab molecule, or in the CH1 and CL domains of the first antigen-binding domain / Fab molecule. Preferably, they are in the CH1 and CL domains of the second antigen-binding domain and (if present) the third antigen-binding domain / Fab molecule. According to the concept of the invention, if the amino acid substitutions as described herein are performed in the second antigen-binding domain (and, if present, the third antigen-binding domain) / Fab molecule, such amino acid substitutions are not performed in the first antigen-binding domain / Fab molecule. Conversely, if the amino acid substitutions as described herein are performed in the first antigen-binding domain / Fab molecule, such amino acid substitutions are not performed in the second antigen-binding domain (and, if present, the third antigen-binding domain) / Fab molecule. Amino acid substitutions are preferably performed in (multispecific) antibodies comprising Fab molecules in which the variable domains VL and VH1 of the Fab light chain and the Fab heavy chain are interchanged.

[0421] In a preferred aspect of the (multispecific) antibody according to the invention, particularly wherein the amino acid substitution as described herein is performed in the second (and, if present, a third) antigen-binding domain / Fab molecule, and the constant domain CL of the second (and, if present, third) Fab molecule is κ isoform. In other aspects of the (multispecific) antibody according to the invention, particularly wherein the amino acid substitution as described herein is performed in the first antigen-binding domain / Fab molecule, and the constant domain CL of the first antigen-binding domain / Fab molecule is κ isoform. In some aspects, the constant domain CL of the second (and, if present, third) antigen-binding domain / Fab molecule and the constant domain CL of the first antigen-binding domain / Fab molecule are κ isoform.

[0422] In one aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0423] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR)1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; and (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11. 3 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7, and HCDR 3 of SEQ ID NO:13 (especially VH, comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21, and LCDR 3 of SEQ ID NO:22, and

[0424] (B) A second antigen-binding domain that binds to a second antigen, particularly a target cell antigen, especially TYRP-1, CEA, GPRC5D or CD19, wherein the second antigen-binding domain is a (conventional) Fab molecule.

[0425] (C) The Fc domain is composed of a first subunit and a second subunit;

[0426] In (B), within the constant domain CL of the second antigen-binding domain, the amino acid at position 124 is replaced by lysine (K) (according to Kabat index number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat index number) (most preferably arginine (R)); and in (B), within the constant domain CH1 of the second antigen-binding domain, the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number); and

[0427] in

[0428] (i) The first antigen-binding domain according to (A) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second antigen-binding domain according to (B), and the second antigen-binding domain according to (B) is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C), or

[0429] (ii) The second antigen-binding domain of (B) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of (A), and the first antigen-binding domain of (A) is fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of (C).

[0430] In a preferred aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising...

[0431] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR)1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; and (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11. 3 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7, and HCDR 3 of SEQ ID NO:13 (especially VH, comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21, and LCDR 3 of SEQ ID NO:22, and

[0432] (B) A second antigen-binding domain and a third antigen-binding domain that bind to a second antigen, particularly a target cell antigen, especially TYRP-1, CEA, GPRC5D or CD19, wherein the second antigen-binding domain and the third antigen-binding domain are each (conventional) Fab molecules.

[0433] (C) The Fc domain is composed of a first subunit and a second subunit;

[0434] In the constant domain CL of the second antigen-binding domain and the third antigen-binding domain according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat numbering) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat numbering) (most preferably replaced by arginine (R)); and in the constant domain CH1 of the second antigen-binding domain and the third antigen-binding domain according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number); and

[0435] in

[0436] (i) The first antigen-binding domain according to (A) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second antigen-binding domain according to (B), and the second antigen-binding domain according to (B) and the third antigen-binding domain according to (B) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C), or

[0437] (ii) The second antigen-binding domain of (B) is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of (A), and the first antigen-binding domain of (A) and the third antigen-binding domain of (B) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of (C).

[0438] In another aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0439] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR)1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; and (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11. 3 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7, and HCDR 3 of SEQ ID NO:13 (especially VH, comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21, and LCDR 3 of SEQ ID NO:22, and

[0440] (B) A second antigen-binding domain that binds to a second antigen, particularly a target cell antigen, especially TYRP-1, CEA, GPRC5D or CD19, wherein the second antigen-binding domain is a (conventional) Fab molecule.

[0441] (C) The Fc domain is composed of a first subunit and a second subunit;

[0442] In (B), within the constant domain CL of the second antigen-binding domain, the amino acid at position 124 is replaced by lysine (K) (according to Kabat index number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat index number) (most preferably arginine (R)); and in (B), within the constant domain CH1 of the second antigen-binding domain, the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number); and

[0443] The first antigen-binding domain of (A) and the second antigen-binding domain of (B) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain of (C).

[0444] According to any of the above, components of a (multispecific) antibody (e.g., Fab molecules, Fc domains) can be fused directly or via various linkers, particularly peptide linkers containing one or more amino acids, typically about 2-20 amino acids, which are described herein or known in the art. Suitable non-immunogenic peptide linkers include, for example, (G4S). n (SG4) n (G4S) n G4 (SG4) n Or (G4S) n G5 peptide linkers, where "n" is typically an integer from 1 to 10, and usually from 2 to 4.

[0445] In one aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0446] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11. 3 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7, and HCDR 3 of SEQ ID NO:13 (especially VH, comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21, and LCDR 3 of SEQ ID NO:22, and

[0447] (B) A second antigen-binding domain and a third antigen-binding domain that bind to TYRP-1, wherein each of the second and third antigen-binding domains is a (conventional) Fab molecule and includes a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region includes the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:15, HCDR 2 of SEQ ID NO:16, and HCDR 3 of SEQ ID NO:17; the light chain variable region includes the light chain complementarity-determining region (LCDR) 1 of SEQ ID NO:19, LCDR 2 of SEQ ID NO:20, and LCDR 3 of SEQ ID NO:21.

[0448] (C) The Fc domain is composed of a first subunit and a second subunit;

[0449] in

[0450] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0451] And further of that

[0452] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0453] In another aspect, the present invention provides a (multispecific) antibody comprising...

[0454] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule, wherein the variable domains VH and VL of the Fab light chain and the Fab heavy chain are interchanged, and the Fab heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19 (especially the amino acid sequence of SEQ ID NO:16), and the light chain variable region comprises the amino acid sequence of SEQ ID NO:11;

[0455] (B) A second antigen-binding domain and a third antigen-binding domain that bind to TYRP-1, wherein the second antigen-binding domain and the third antigen-binding domain are each (conventional) Fab molecules and contain a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region contains the amino acid sequence of SEQ ID NO:27 and the light chain variable region contains the amino acid sequence of SEQ ID NO:31.

[0456] (C) The Fc domain is composed of a first subunit and a second subunit;

[0457] in

[0458] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0459] And further of that

[0460] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0461] In another aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0462] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11. 3 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7, and HCDR 3 of SEQ ID NO:13 (especially VH, comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21, and LCDR 3 of SEQ ID NO:22, and

[0463] (B) A second antigen-binding domain and a third antigen-binding domain that bind to CEA, wherein each of the second and third antigen-binding domains is a (conventional) Fab molecule and comprises: (i) VH, which comprises HCDR 1 of SEQ ID NO:53, HCDR 2 of SEQ ID NO:54, and HCDR 3 of SEQ ID NO:55; and VL, which comprises LCDR 1 of SEQ ID NO:57, LCDR 2 of SEQ ID NO:58, and LCDR 3 of SEQ ID NO:59; (ii) VH, which comprises HCDR 1 of SEQ ID NO:105, HCDR 2 of SEQ ID NO:106, and HCDR 3 of SEQ ID NO:107; and VL, which comprises LCDR 1 of SEQ ID NO:109, LCDR 2 of SEQ ID NO:110, and LCDR 3 of SEQ ID NO:111; or (iii) VH, which comprises HCDR 1 of SEQ ID NO:113, HCDR 1 of SEQ ID NO:114, and LCDR 3 of SEQ ID NO:115; HCDR 2 of SEQ ID NO:114 and HCDR 3 of SEQ ID NO:115; and VL, which contains LCDR 1 of SEQ ID NO:117, LCDR 2 of SEQ ID NO:118 and LCDR 3 of SEQ ID NO:119;

[0464] (C) The Fc domain is composed of a first subunit and a second subunit;

[0465] in

[0466] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0467] And further of that

[0468] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0469] In another aspect, the present invention provides a (multispecific) antibody comprising...

[0470] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule, wherein the variable domains VH and VL of the Fab light chain and the Fab heavy chain are interchanged, and the Fab heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19 (especially the amino acid sequence of SEQ ID NO:16), and the light chain variable region comprises the amino acid sequence of SEQ ID NO:11;

[0471] (B) A second antigen-binding domain and a third antigen-binding domain that bind to CEA, wherein the second antigen-binding domain and the third antigen-binding domain are each (conventional) Fab molecules and comprise: (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:56 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:60; (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:108 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:112; or (iii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:116 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:120;

[0472] (C) The Fc domain is composed of a first subunit and a second subunit;

[0473] in

[0474] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0475] And further of that

[0476] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0477] In another aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0478] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11. 3 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7, and HCDR 3 of SEQ ID NO:13 (especially VH, comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21, and LCDR 3 of SEQ ID NO:22, and

[0479] (B) A second antigen-binding domain and a third antigen-binding domain that bind to GPRC5D, wherein the second antigen-binding domain and the third antigen-binding domain are each (conventional) Fab molecules and contain VH and VL, wherein the VH contains HCDR 1 of SEQ ID NO:61, HCDR 2 of SEQ ID NO:62 and HCDR 3 of SEQ ID NO:63; and the VL contains LCDR 1 of SEQ ID NO:65, LCDR 2 of SEQ ID NO:66 and LCDR 3 of SEQ ID NO:67;

[0480] (C) The Fc domain is composed of a first subunit and a second subunit;

[0481] in

[0482] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0483] And further of that

[0484] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0485] In another aspect, the present invention provides a (multispecific) antibody comprising...

[0486] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule, wherein the variable domains VH and VL of the Fab light chain and the Fab heavy chain are interchanged, and the Fab heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19 (especially the amino acid sequence of SEQ ID NO:16), and the light chain variable region comprises the amino acid sequence of SEQ ID NO:11;

[0487] (B) A second antigen-binding domain and a third antigen-binding domain that bind to GPRC5D, wherein the second antigen-binding domain and the third antigen-binding domain are each (conventional) Fab molecules and contain (i) a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region contains the amino acid sequence of SEQ ID NO:64 and the light chain variable region contains the amino acid sequence of SEQ ID NO:68.

[0488] (C) The Fc domain is composed of a first subunit and a second subunit;

[0489] in

[0490] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0491] And further of that

[0492] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0493] In one aspect, the present invention provides a (multispecific) antibody, said (multispecific) antibody comprising

[0494] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule in which the variable domains VH and VL of the Fab heavy chain and light chain are interchanged, and includes (i) a heavy chain variable region (VH) selected from the group consisting of: (a) a VH containing the heavy chain complementarity-determining region (HCDR) 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10; (b) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:12; (c) a VH containing HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:5, and HCDR 3 of SEQ ID NO:9; (d) a VH containing HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:6, and HCDR 3 of SEQ ID NO:11. 3 or (e) VH, comprising HCDR 1 of SEQ ID NO:3, HCDR 2 of SEQ ID NO:7, and HCDR 3 of SEQ ID NO:13 (especially VH, comprising HCDR 1 of SEQ ID NO:2, HCDR 2 of SEQ ID NO:4, and HCDR 3 of SEQ ID NO:10); and (ii) light chain variable region (VL), comprising light chain complementarity determination region (LCDR) 1 of SEQ ID NO:20, LCDR 2 of SEQ ID NO:21, and LCDR 3 of SEQ ID NO:22, and

[0495] (B) A second antigen-binding domain and a third antigen-binding domain that bind to CD19, wherein the second antigen-binding domain and the third antigen-binding domain are each (conventional) Fab molecules and comprise: (i) VH, which comprises HCDR 1 of SEQ ID NO:75, HCDR 2 of SEQ ID NO:76, and HCDR 3 of SEQ ID NO:77; and VL, which comprises LCDR1 of SEQ ID NO:79, LCDR 2 of SEQ ID NO:80, and LCDR 3 of SEQ ID NO:81; or (ii) VH, which comprises HCDR 1 of SEQ ID NO:83, HCDR 2 of SEQ ID NO:84, and HCDR 3 of SEQ ID NO:85; and VL, which comprises LCDR 1 of SEQ ID NO:87, LCDR 2 of SEQ ID NO:88, and LCDR 3 of SEQ ID NO:89 (especially VH, which comprises HCDR 1 of SEQ ID NO:75, HCDR 2 of SEQ ID NO:76, and LCDR 3 of SEQ ID NO:79). 2 and HCDR 3 of SEQ ID NO:77; and VL, which includes LCDR 1 of SEQ ID NO:79, LCDR 2 of SEQ ID NO:80 and LCDR 3 of SEQ ID NO:81);

[0496] (C) The Fc domain is composed of a first subunit and a second subunit;

[0497] in

[0498] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0499] And further of that

[0500] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0501] In another aspect, the present invention provides a (multispecific) antibody comprising...

[0502] (A) A first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain is a Fab molecule, wherein the variable domains VH and VL of the Fab light chain and the Fab heavy chain are interchanged, and the Fab heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:19 (especially the amino acid sequence of SEQ ID NO:16), and the light chain variable region comprises the amino acid sequence of SEQ ID NO:11;

[0503] (B) A second antigen-binding domain and a third antigen-binding domain that bind to CD19, wherein the second antigen-binding domain and the third antigen-binding domain are each (conventional) Fab molecules and comprise: (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:78 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:82; or (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:86 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:90 (particularly the heavy chain variable region comprising the amino acid sequence of SEQ ID NO:78 and the light chain variable region comprising the amino acid sequence of SEQ ID NO:82);

[0504] (C) The Fc domain is composed of a first subunit and a second subunit;

[0505] in

[0506] In the constant domain CL of the second and third antigen-binding domains according to (B), the amino acid at position 124 is replaced by lysine (K) (according to Kabat number) and the amino acid at position 123 is replaced by either lysine (K) or arginine (R) (according to Kabat number) (most preferably replaced by arginine (R)), and in the constant domain CH1 of the second and third antigen-binding domains according to (B), the amino acid at position 147 is replaced by glutamic acid (E) (according to Kabat EU index number) and the amino acid at position 213 is replaced by glutamic acid (E) (according to Kabat EU index number);

[0507] And further of that

[0508] According to (B), the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen-binding domain of the Fab heavy chain according to (A), and the first antigen-binding domain and the third antigen-binding domain according to (A) are each fused at the C-terminus of the Fab heavy chain to the N-terminus of one of the subunits of the Fc domain according to (C).

[0509] In one aspect of these aspects of the invention, in the first subunit of the Fc domain, the threonine residue at position 366 is replaced with a tryptophan residue (T366W); while in the second subunit of the Fc domain, the tyrosine residue at position 407 is replaced with a valine residue (Y407V), and optionally, the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A) (according to the Kabat EU index number).

[0510] In another aspect of these aspects of the invention, in the first subunit of the Fc domain, the serine residue at position 354 is replaced by a cysteine ​​residue (S354C) or the glutamate residue at position 356 is replaced by a cysteine ​​residue (E356C) (particularly the serine residue at position 354 is replaced by a cysteine ​​residue), and in the second subunit of the Fc domain, the tyrosine residue at position 349 is replaced by a cysteine ​​residue (Y349C) (according to the Kabat EU index number).

[0511] In yet another aspect of these aspects of the invention, in each of the first and second subunits of the Fc domain, the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced with a glycine residue (P329G) (according to the Kabat EU index number).

[0512] In yet another aspect of these aspects of the invention, the Fc domain is the human IgG1 Fc domain.

[0513] In specific respects, the (multispecific) antibody comprises a polypeptide (containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:34, a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:33, and a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:32. In another specific aspect, the (multispecific) antibody comprises a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (especially the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:34 (especially two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:33 and a polypeptide comprising the amino acid sequence of SEQ ID NO:32.

[0514] In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and TYRP-1, the antibody comprising a polypeptide (containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:34, a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:33, and a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:32. In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and TYRP-1, the antibody comprising a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (particularly the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:34 (particularly two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:33, and a polypeptide comprising the amino acid sequence of SEQ ID NO:32.

[0515] In another specific aspect, the (multispecific) antibody comprises a polypeptide (containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:71, a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:69, and a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:70. In another specific aspect, the (multispecific) antibody comprises a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (especially the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:71 (especially two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:69 and a polypeptide comprising the amino acid sequence of SEQ ID NO:70.

[0516] In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and CEA, the antibody comprising a polypeptide (comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:71, a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:69, and a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:70. In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and CEA, the antibody comprising a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (particularly the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:71 (particularly two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:69, and a polypeptide comprising the amino acid sequence of SEQ ID NO:70.

[0517] In yet another specific aspect, the (multispecific) antibody comprises a polypeptide (containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:74, a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:72, and a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:73. In another specific aspect, the (multispecific) antibody comprises a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (especially the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:74 (especially two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:72 and a polypeptide comprising the amino acid sequence of SEQ ID NO:73.

[0518] In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and GPRC5D, the antibody comprising a polypeptide (comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:74, a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:72, and a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:73. In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and GPRC5D, the antibody comprising a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (particularly the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:74 (particularly two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:72, and a polypeptide comprising the amino acid sequence of SEQ ID NO:73.

[0519] In another specific aspect, the (multispecific) antibody comprises a polypeptide (containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:94, a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:91 or SEQ ID NO:92, particularly the sequence of SEQ ID NO:91), and a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:93. In another specific aspect, the (multispecific) antibody comprises a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (especially the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:94 (especially two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:91 or SEQ ID NO:92 (especially the sequence of SEQ ID NO:91), and a polypeptide comprising the amino acid sequence of SEQ ID NO:93.

[0520] In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and CD19, the antibody comprising a polypeptide (comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:94, a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:91 or SEQ ID NO:92, particularly the sequence of SEQ ID NO:91), and a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:93. In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and CD19, the antibody comprising a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (especially the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:94 (especially two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:91 or SEQ ID NO:92 (especially the sequence of SEQ ID NO:91), and a polypeptide comprising the amino acid sequence of SEQ ID NO:93.

[0521] In another specific aspect, the (multispecific) antibody comprises a polypeptide (containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40, particularly the sequence of SEQ ID NO:37), a polypeptide (particularly two polypeptides) containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:98, a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:95 or SEQ ID NO:96, particularly the sequence of SEQ ID NO:95), and a polypeptide containing at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:97. In another specific aspect, the (multispecific) antibody comprises a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (especially the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:98 (especially two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:95 or SEQ ID NO:96 (especially the sequence of SEQ ID NO:95), and a polypeptide comprising the amino acid sequence of SEQ ID NO:97.

[0522] In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and CD19, the antibody comprising a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:40 (particularly the sequence of SEQ ID NO:37), a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:98 (particularly two polypeptides), a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:95 or SEQ ID NO:96 (particularly the sequence of SEQ ID NO:95), and a polypeptide comprising at least 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the sequence of SEQ ID NO:97. In one aspect, the present invention provides a (multispecific) antibody that binds to CD3 and CD19, the antibody comprising a polypeptide comprising an amino acid sequence comprising the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40 (especially the amino acid sequence of SEQ ID NO:37), a polypeptide comprising the amino acid sequence of SEQ ID NO:98 (especially two polypeptides), a polypeptide comprising the amino acid sequence of SEQ ID NO:95 or SEQ ID NO:96 (especially the sequence of SEQ ID NO:95), and a polypeptide comprising the amino acid sequence of SEQ ID NO:97.

[0523] 8. Variants of the Fc domain

[0524] In a preferred aspect, the (multispecific) antibody of the present invention comprises an Fc domain consisting of a first subunit and a second subunit.

[0525] The Fc domain of a (multispecific) antibody consists of a pair of polypeptide chains comprising the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which contains CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain can stably associate with each other. In one aspect, the (multispecific) antibody of the present invention comprises no more than one Fc domain.

[0526] In one aspect, the Fc domain of the (multispecific) antibody is an IgG Fc domain. In a preferred aspect, the Fc domain is an IgG1 Fc domain. In another aspect, the Fc domain is an IgG4 Fc domain. In a more specific aspect, the Fc domain is an IgG4 Fc domain containing an amino acid substitution (specifically, amino acid substitution S228P) at position S228 (Kabat EU index number). This amino acid substitution reduces in vivo Fab arm exchange of the IgG4 antibody (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In another preferred aspect, the Fc domain is a human Fc domain. In an even more preferred aspect, the Fc domain is a human IgG1 Fc domain. An exemplary sequence of the human IgG1 Fc region is given in SEQ ID NO:47.

[0527] a) Fc domain modification to promote heterodimerization

[0528] The (multispecific) antibody according to the invention comprises a different antigen-binding domain that can fuse with one or the other of the two subunits of the Fc domain, thus the two subunits of the Fc domain are typically contained in two different polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization result in several possible combinations of the two polypeptides. To improve the yield and purity of the (multispecific) antibody in recombinant production, it is therefore advantageous to introduce modifications into the Fc domain of the (multispecific) antibody protein that promote the association of the desired polypeptide.

[0529] Therefore, in a preferred aspect, the Fc domain of the (multispecific) antibody according to the invention comprises modifications that promote association between the first and second subunits of the Fc domain. The most extensive protein-protein interaction site between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Therefore, in one aspect, the modification is in the CH3 domain of the Fc domain.

[0530] Several methods exist for modifying the CH3 domain of the Fc domain to achieve heterodimerization, and these methods are described in detail, for example, in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012058768, WO2013157954, and WO 2013096291. Typically, in all such approaches, the CH3 domains of the first subunit and the second subunit of the Fc domain are engineered in a complementary manner, such that each CH3 domain (or the heavy chain containing it) is no longer homodimerized with itself, but is instead forced to heterodimerize with other complementaryly engineered CH3 domains (so that the first and second CH3 domains heterodimerize and no homodimers are formed between the two first or two second CH3 domains). These different approaches to achieving improved heavy chain heterodimerization are considered as different substitution schemes combined with heavy-light chain modifications in (multispecific) antibodies (e.g., VH and VL exchange / replacement in one binding arm and the introduction of substitutions of charged amino acids with opposite charges at the CH1 / CL interface), which reduce heavy chain / light chain mismatches and Bence Jones-type byproducts.

[0531] In one specific aspect, the modification that promotes association between the first and second subunits of the Fc domain is a so-called "mortar and pestle structure" modification, which includes a "mortar" modification in one of the two subunits of the Fc domain and a "mortar" modification in the other of the two subunits of the Fc domain.

[0532] The pestle-and-mortar structure technique is described, for example, in US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, this method involves introducing a protrusion (“pestle”) at the interface of a first polypeptide and a corresponding cavity (“mortar”) at the interface of a second polypeptide, such that the protrusion can be positioned within the cavity to promote the formation of heterodimers and inhibit the formation of homodimers. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensating cavity having the same or similar size as the protrusion is created at the interface of the second polypeptide by replacing the large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). ...

Claims

1. An antibody that binds to CD3, wherein the antibody comprises (i) a heavy chain variable region (VH) comprising a heavy chain complementarity-determining region (HCDR) 1 as shown in SEQ ID NO: 2, an HCDR 2 as shown in SEQ ID NO: 4, and an HCDR 3 as shown in SEQ ID NO: 10; and (ii) a light chain variable region (VL) comprising a light chain complementarity-determining region (LCDR) 1 as shown in SEQ ID NO: 20, an LCDR 2 as shown in SEQ ID NO: 21, and an LCDR 3 as shown in SEQ ID NO:

22.

2. The antibody of claim 1, wherein the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 16; and / or the VL comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:

23.

3. An antibody that binds to CD3, wherein the antibody comprises a VH sequence as shown in SEQ ID NO: 16 and a VL sequence as shown in SEQ ID NO:

23.

4. The antibody according to any one of claims 1 to 3, comprising an Fc domain composed of a first subunit and a second subunit.

5. The antibody according to claim 4, wherein the Fc domain is an IgG Fc domain.

6. The antibody according to claim 4 or 5, wherein the Fc domain is an IgG1 Fc domain.

7. The antibody according to any one of claims 4 to 6, wherein the Fc domain is a human Fc domain.

8. The antibody according to any one of claims 4 to 7, wherein the Fc domain is a human IgG1 Fc domain.

9. The antibody according to any one of claims 4 to 8, wherein the Fc comprises a modification that promotes association between the first subunit and the second subunit of the Fc domain.

10. The antibody according to any one of claims 4 to 9, wherein in the CH3 domain of the first subunit of the Fc domain, amino acid residues are replaced by amino acid residues having a larger side chain volume, thereby creating a protrusion within the CH3 domain of the first subunit, the protrusion being localized in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain, amino acid residues are replaced by amino acid residues having a smaller side chain volume, thereby creating a cavity within the CH3 domain of the second subunit, the protrusion within the CH3 domain of the first subunit being localized within the cavity.

11. The antibody according to any one of claims 4 to 10, wherein in the first subunit of the Fc domain, the threonine residue at position 366 is replaced by a tryptophan residue (T366W), and in the second subunit of the Fc domain, the tyrosine residue at position 407 is replaced by a valine residue (Y407V), according to the Kabat EU index number.

12. The antibody of claim 11, wherein, (a) In the second subunit of the Fc domain, additionally, the threonine residue at position 366 is replaced by a serine residue (T366S) and the leucine residue at position 368 is replaced by an alanine residue (L368A); and / or (b) In the first subunit of the Fc domain, additionally, the serine residue at position 354 is replaced by a cysteine ​​residue (S354C) or the glutamic acid residue at position 356 is replaced by a cysteine ​​residue (E356C), and in the second subunit of the Fc domain, additionally, the tyrosine residue at position 349 is replaced by a cysteine ​​residue (Y349C), according to the Kabat EU index number.

13. The antibody according to any one of claims 4 to 12, wherein the Fc domain comprises one or more amino acid substitutions, the one or more amino acid substitutions reducing binding to the Fc receptor and / or reducing effector function.

14. The antibody according to any one of claims 4 to 13, wherein the Fc domain comprises an amino acid substitution at a position selected from the group consisting of E233, L234, L235, N297, P331 and P329, according to the Kabat EU index number.

15. The antibody according to any one of claims 4 to 14, wherein the Fc domain comprises an amino acid substitution at a position selected from the group consisting of L234, L235 and P329, according to the Kabat EU index number.

16. The antibody according to any one of claims 4 to 15, wherein each subunit of the Fc domain comprises L234A, L235A, and P329G amino acid substitutions, according to the Kabat EU index number.

17. An isolated polynucleotide encoding an antibody according to any one of claims 1 to 16.

18. A host cell comprising the isolated polynucleotide according to claim 17.

19. A method for producing an antibody that binds to CD3, comprising the following steps: The host cells according to claim 18 are cultured under conditions suitable for expressing the antibody.

20. The method of claim 19, further comprising the following steps: The antibody was recovered.

21. An antibody that binds to CD3, produced by the method according to claim 20.

22. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 16 or 21 and a pharmaceutical carrier.

Citation Information

Patent Citations

  • CS176501B1

  • Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof

    EP0404097A2

  • Methods for producing polypeptides by regulating polypeptide association

    EP1870459A1

  • RNA-coded antibody

    EP2101823B1

  • Glycoprotein compositions

    US20030157108A1